Oral Delivery of Therapeutics
Combining fatty acids and oral absorption enhancers like SNAC and sodium caprate enhances the oral delivery of therapeutic agents by protecting them from stomach degradation and improving absorption, resulting in increased bioavailability and effective glucose control.
Patent Information
- Application Number
- JP2024547813
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-21
- Filing Date
- 2022-10-19
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 2024541120000021 
Figure 2024541120000022 
Figure 2024541120000023
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to International Patent Application No. PCT / CN2021 / 125360, filed October 21, 2021, the contents of which are incorporated herein by reference in their entirety. [Background technology]
[0002] In various embodiments, the present invention relates generally to oral delivery of therapeutic agents.
[0003] For drug administration, delivery by the oral route is the most preferred, as it offers several advantages, including improved patient compliance, ease of administration, and usually lower manufacturing, storage and distribution costs.
[0004] However, few large molecules can be administered orally due to: 1) degradation by stomach acidity and enzymes in the gastrointestinal (GI) tract prior to systemic penetration; 2) poor absorption through epithelial cells lining absorptive surfaces such as the GI tract; and 3) post-absorptive degradation, such as first-pass metabolism. Summary of the Invention
[0005] In various embodiments, the present disclosure relates to oral delivery of therapeutic agents, particularly molecules such as polypeptides, that have a high molecular weight or that are poorly absorbed by oral administration. The present disclosure is based, in part, on the unexpected discovery that the combination of certain fatty acids and oral absorption enhancers can achieve a synergistic effect that enhances the overall oral absorption of therapeutic agents.
[0006] In some embodiments, the present disclosure relates to the use of a mixture of functional excipients in combination with formulation methods to significantly enhance gastrointestinal absorption of biological therapeutics, either alone or in combination, to alter approaches to curing and ameliorating diseases.
[0007] As used herein, biological therapeutics include, but are not limited to, carbohydrates, peptides, proteins, enzymes, antibodies, drug conjugates, vaccines, nucleic acids, and nucleic acid-based gene therapeutics. For example, biological therapeutics include, but are not limited to, unfractionated heparin, low molecular weight heparin, synthetic heparin, growth hormone, growth factor, insulin, insulin icodec, interferon, interlukin, follicle stimulating hormone, gonadotropin, erythropoietin, incretin, semaglutide, liraglutide, exenatide, tirzepatide, PYY, oxyntomodulin, GLP-1, GLP-2, calcitonin, PHT and analogs, vancomycin, daptomycin, micafungin, anidulafungin, capsofungin, leuprolide, and monoclonal antibodies.
[0008] Functional excipients useful herein include, but are not limited to, these molecules and their analogs: sodium 8-(2-hydroxybenzoyl)octanoate (SNAC), sodium 10-((2-hydroxybenzoyl)amino)decanoate (SNAD), sodium 8-(N-2)-hydroxy-5-chlorobenzoyl)-aminocaprylate (5CNAC), sodium N-(4-chlorosalicyloyl)-4-aminobutyrate (4-CNAB), sodium N-[8-(2-hydroxy-4-methoxy)benzoyl]aminocaprylate (4-MOAC), and bis-3,6(4-fumarylaminobutyl)-2,5-diketopiperazine. Additionally, functional excipients useful herein include, for example, straight chain fatty acids and their salts, the number of carbons in the aliphatic chain ranging from 2 to 20.
[0009] In certain exemplary embodiments, the drug is administered using an oral dosage form that contains an active agent, an incretin therapeutic ("incretin"), such as a GLP-1 receptor agonist (GLP-1 RA), functional excipients, such as a mixture of fatty acids and surfactants, and common excipients used in oral dosage forms, such as tablets and capsules. Functional excipients useful in the present invention include, but are not limited to, sodium N-[8(-2-hydroxybenzoyl)amino]caprylate (SNAC), 8-(N-2-hydroxy-5-chlorobenzoyl)aminocaprylic acid (5-CNAC), [bis-3,6(4-fumarylaminobutyl)-2,5-diketopiperazine, salts of straight chain fatty acids, and combinations thereof. In other embodiments, the oral dosage form can include combinations of active agents, such as, but are not limited to, a GLP-1 RA and an SGLT-2 inhibitor, a GLP-1 RA and a DPP4 inhibitor, and a GLP-1 RA and insulin. Incretins useful in embodiments herein include, but are not limited to, GLP-1, GIP, GLP-1 / GIP agonists. Incretins useful in embodiments herein also include GIP, GLP-1 / GIP agonists in clinical trials, GLP-1 RA, and GLP-1 analogs including, but not limited to, semaglutide, liraglutide, dulaglutide, lixisenatide, exenatide, and the like. SGLT2 inhibitors useful in embodiments herein include, but are not limited to, empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, and the like. DPP4 inhibitors useful in embodiments herein include, but are not limited to, sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin, and the like. Insulin and insulin analogs useful in embodiments herein include, but are not limited to, insulin icodec. In yet other embodiments, the present disclosure relates to methods for preparing oral dosage forms such as tablets and capsules. In further embodiments, the functional excipient mixtures and preparation methods described herein may also be applied to other routes of administration.
[0010] Exemplary embodiments of the present disclosure are also set forth in claims 1 to 43 herein.
[0011] It is to be understood that both the foregoing summary of the invention and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed. [Brief description of the drawings]
[0012] [Figure 1] Figure 1 compares the mean plasma semaglutide pharmacokinetics on a linear scale following oral administration of (1) a formulation containing 10 mg semaglutide and 300 mg SNAC alone, or (2) a formulation containing 10 mg semaglutide, 300 mg SNAC and 150 mg sodium caprate. Error bars indicate the standard deviation of semaglutide concentrations at the indicated times. [Diagram 2] Figure 2 depicts a graph showing the plasma semaglutide concentration profile over time on a log-linear scale following oral administration of (1) 10 mg semaglutide and 300 mg SNAC, or (2) 10 mg semaglutide, 300 mg SNAC and 150 mg sodium caprate. Error bars indicate the standard deviation of the semaglutide concentrations at the indicated times. [Diagram 3] Figure 3 shows the time profiles of glucose concentrations during oral glucose tests in healthy beagle dogs after oral administration of (1) negative control, (2) 10 mg semaglutide and 300 mg SNAC, or (3) 10 mg semaglutide, 300 mg SNAC and 150 mg sodium caprate. [Figure 4] Figure 4 shows a graph showing the plasma semaglutide concentration profile over time comparing oral administration of 7 mg semaglutide formulated by lyophilisation in 300 mg SNAC / 150 mg C10 with oral administration of 7 mg semaglutide in a commercially available tablet (Rebelsus). [Diagram 5]Figure 5 shows a graph showing the plasma semaglutide concentration profile over time comparing oral administration of 10 mg semaglutide formulated in 300 mg SNAC / 150 mg C10 by lyophilisation with oral administration by simple mixing. [Figure 6] Figure 6 shows a graph showing the plasma semaglutide concentration profile over time compared to oral administration of 10 mg semaglutide formulated in 300 mg SNAC, 300 mg C10, or 300 mg SNAC / 150 mg C10, each prepared by lyophilization. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] The present disclosure generally relates to oral delivery of therapeutic agents. As detailed herein, the inventors have discovered that the combination of semaglutide with SNAC and sodium caprate unexpectedly results in higher drug absorption and more effective glucose control than a formulation containing semaglutide and SNAC alone. The effective enhancement based on the plasma concentration of semaglutide is about 5-fold. Inter-individual variability is also significantly reduced. Furthermore, the superior pharmacological effect of semaglutide based on oral glucose tolerance test (oGTT) was also demonstrated with the combination of semaglutide with SNAC and sodium caprate. Furthermore, the data herein show that the use of freeze-drying method in the preparation of the formulation herein is beneficial in achieving higher exposure of semaglutide compared to the equivalent formulation prepared using a simple blending method. Furthermore, the data herein demonstrate that the use of SNAC and sodium caprate achieved a synergistic effect of enhancing the oral exposure of semaglutide.
[0014] In a broad aspect, the present invention provides a pharmaceutical composition comprising a therapeutic agent (e.g., any of those described herein) and one or more, particularly two or more functional excipients (e.g., any of those described herein).Unless otherwise stated in the context, as used herein, a functional excipient refers to an excipient that can increase the oral bioavailability of a therapeutic agent.For example, in some embodiments, a functional excipient refers to an excipient that can increase the bioavailability of a GLP-1 agonist of the composition after oral administration.
[0015] Typically, a pharmaceutical composition comprises two or more functional excipients that can synergistically enhance the oral absorption of a therapeutic agent. In some embodiments, one or more functional excipients comprises a fatty acid of formula I: RCOOH, where R represents an aliphatic group, or a pharma- ceutically acceptable salt thereof. In some embodiments, one or more functional excipients comprises a fatty acid of formula II: [ka] or a pharma- ceutically acceptable salt thereof, wherein n is an integer selected from 0, 1, 2, 3, or 4; 1 are independently OH, NH2, NH(C 1~4 alkyl), N(C 1~4 Alkyl)(C 1~4 Alkyl), halogen (e.g., Cl), C 1~4 Alkyl, or C 1~4 Alkoxy (e.g., OCH3), L 1 is a substituted or unsubstituted C2-C 16 Alkylene, or substituted or unsubstituted C2-C 16 alkenylene). Typically, the pharmaceutical composition is formulated for oral administration. Preferably, a therapeutically effective plasma concentration of the therapeutic agent can be achieved following oral administration of the pharmaceutical composition of the present invention.
[0016] In some embodiments, the disclosure provides a method for treating a pulmonary artery disease comprising administering to a patient a therapeutic agent comprising: (a) a therapeutic agent (e.g., any of those described herein); (b) a fatty acid of formula I: RCOOH, where R represents an aliphatic group, or a pharma- ceutically acceptable salt thereof; and (c) a compound of formula II: [ka] or a pharma- ceutically acceptable salt thereof, wherein n is an integer selected from 0, 1, 2, 3, or 4, and 1 are independently OH, NH2, NH(C 1~4 alkyl), N(C 1~4 Alkyl)(C 1~4 Alkyl), halogen (e.g., Cl), C 1~4 Alkyl, or C 1~4 Alkoxy (e.g., OCH3), L 1 is a substituted or unsubstituted C2-C 16 Alkylene, or substituted or unsubstituted C2-C 16 alkenylene).
[0017] Treatment Therapeutic agents useful in the pharmaceutical compositions described herein are not particularly limited. For example, therapeutic agents can include carbohydrates, peptides, proteins, antibodies, vaccines, nucleic acids, and the like. In some embodiments, the therapeutic agent can be a biological therapeutic agent described herein. In some embodiments, the therapeutic agent can be a large molecule, for example, having a molecular weight of 2,000 daltons or more, 3,000 daltons or more, 10,000 daltons or more, or 100,000 daltons or more.
[0018] For example, in some embodiments, the therapeutic agent may be a heparin (eg, unfractionated heparin, low molecular weight heparin, synthetic heparin such as fondaparinux) or a carbohydrate such as glucosamine.
[0019] In some embodiments, a therapeutic agent may be a polypeptide (also referred to herein as a peptide), including proteins and antibodies. Polypeptides useful in embodiments herein are not limited and include, for example, the following agents: 1. GLP-1 and its analogues a) GLP-1 b) Semaglutide c) Liraglutide d) Exenatide e) Tirzepatide f) Lixisenatide g) Efinopegdutide h) Kota Dutchid 2. Teduglutide 3. Pramlintide 4. PYY 5. Oxyntomodulin 6. Glucagon 7. Calcitonin 8. Octreotide 9. PYH and its analogues a) Teriparatide 10. Etelcalcetide 11. Oxytocin 12. Antibiotics a) Vancomycin b) Daptomycin c) Dalbavancin d) Oritavancin e) Telavancin 13. Antifungal drugs a) Micafungin b) Anidulafungin c) Capsofungin 14. Vasopressin 15. Leuprolide 16. Nesiritide 17. Enfuvirtide 18. Growth hormone and its analogues 19. Pegvisomant 20. Mecasermin (rhlGF-1) 21. GnRH a) Histrelin 22. Divothermin-α 23. Paris Fermin 24. Becaplermin 2 25. Adrenocorticotropic hormone 26. Somatostatin 27. Oxodotreotide 28. Pasireotide 29. Trypsin 30. Insulin and its analogues a) Insulin b) Insulin Icodex c) Insulin detemir d) Insulin glargine e) Insulin lispro f) Insulin glulisine g) Insulin aspart 31. Interferon a) Interferon alfacon 1 b) Interferon-α2a c) Interferon-α2b d) Interferon-αn3 e) Interferon-β1a f) Interferon-β1b g) Interferon-gamma 1b 32. Interlude a) Oprelvekin h) Aldesleukin i) Denileukin 33. Follicle-stimulating hormone 34. Human chorionic gonadotropin 35. Lutropin-α 36. Erythropoietin 37. Epoetin-α 38. Darbepoetin-α 39. Filgrastim 40. Pegfilgrastim 41. Sargramostim 42. Alteplase 43. Reteplase 44. Tenecteplase 45. Urokinase 46.Factor VIIa 47.Factor VIII 48.Factor IX 49. Antithrombin III 50. Protein C 51. Drotrecogin-α 52. β-Glucocerebrosidase 53. Alglucosidase-α 54. Laronidase 55. Idursulfase 56. Galsulfaza 57. Agalsidase-β 58. Alpha-1-Protease Inhibitors 59. Lactase 2 60. Pancreatic enzymes 61. Adenosine deaminase 62. Immunoglobulin 63. Albumin 64. Lepirudin 65. Bivalirudin 66.Streptokinase 67. Anistreplase 68. Crizanlizumab 69. Etanercept 70. Adalimumab 71. Infliximab 72. Bevacizumab 73. Trastuzumab 74. Rituximab 75. Copaxone 76. Pachisiran 77. Gibosiran 78. Lumasilan
[0020] In some embodiments, the therapeutic agent can also include a vaccine. In some embodiments, the therapeutic agent can also include a nucleic acid.
[0021] In some preferred embodiments, the therapeutic agent can include an incretin therapeutic agent.For example, in some preferred embodiments, the therapeutic agent can include a glucagon-like peptide-1 (GLP-1) receptor agonist, such as any of those described herein, or any of those described in U.S. Patent Nos. 10,960,052, 8,129,343, 8,536,122, 9,278,123, 10,086,047, 10,278,923, and 10,933,120, the entire contents of each of which are incorporated herein by reference.In some preferred embodiments, the therapeutic agent can include semaglutide, liraglutide, dulaglutide, lixisenatide, or exenatide. Other incretins and peptides include, but are not limited to, PYY and PYY analogs; agonists at the GLP-1 / GIP receptor, such as, but not limited to, tirzepatide, CT-388, SCO-094; agonists at the GLP-1 / GCCR receptor, such as, but not limited to, efinopeglutide, IB 1362.
[0022] In some preferred embodiments, the pharmaceutical compositions herein may include a GLP-1 receptor agonist as the only therapeutic agent. In some embodiments, the pharmaceutical compositions herein may include a GLP-1 receptor agonist as a therapeutic agent in combination with one or more other therapeutic agents useful for the treatment of diabetes, such as therapeutic agents known in the art. In some embodiments, the one or more other therapeutic agents include (1) an SGLT-2 inhibitor, such as empagliflozin, canagliflozin, dapagliflozin, or ertugliflozin; (2) a DPP-4 inhibitor, such as sitagliptin, vildagliptin, saxagliptin, linagliptin, or alogliptin; (3) an insulin or insulin analog (e.g., insulin icodec); (4) GIP, glucose-dependent insulinotropic polypeptide; and / or (5) an amylin or an amylin analog. In some embodiments, the one or more other therapeutic agents can also include: (1) a biguanide; (2) a thiazolidinedione; (3) a DPP-4 inhibitor; (4) PYY; and (5) a sulfonylurea.
[0023] In some embodiments, the pharmaceutical compositions herein can include a GLP-1 receptor agonist as one therapeutic agent in combination with one or more other therapeutic agents useful in the treatment of neurological disorders, such as Alzheimer's disease. For example, in some embodiments, the pharmaceutical compositions herein can include semaglutide as one therapeutic agent in combination with (1) a cholinesterase inhibitor (e.g., Aricept, Exelon, Razadyne), (2) a glutamate regulator (e.g., Namenda), and / or (3) an orexin receptor antagonist (e.g., Belsomra).
[0024] In a more preferred embodiment, the therapeutic agent herein may include semaglutide. Semaglutide as used herein is not limited to a particular form. For example, in some embodiments, semaglutide may be in the form of a pharma- ceutically acceptable salt, such as a sodium salt. Semaglutide is sold in the United States under several trade names, including the oral Ryvelsus tablet formulation. See the 2021 version of the Ryvelsus prescribing information approved by the U.S. Food and Drug Administration, the contents of which are incorporated herein by reference in their entirety. As described therein, the peptide backbone of semaglutide is produced by yeast fermentation. The primary sustaining mechanism of action of semaglutide is albumin binding, which is promoted by modifying lysine 26 with a hydrophilic spacer and a C18 fatty diacid. Additionally, semaglutide is modified at position 8 to stabilize it against degradation by the enzyme dipeptidyl peptidase 4 (DPP-4). A small modification was made at position 34 to allow only one fatty diacid to be bound. Its molecular formula is C187H291N45O59 and its molecular weight is 4113.58 g / mol. Its structure is shown below: [ka]
[0025] In some preferred embodiments, the pharmaceutical compositions herein may include semaglutide as the only therapeutic agent. In some embodiments, the pharmaceutical compositions herein may include semaglutide as a therapeutic agent in combination with one or more other therapeutic agents useful for the treatment of diabetes, such as therapeutic agents known in the art. In some embodiments, the one or more other therapeutic agents include (1) an SGLT-2 inhibitor, such as empagliflozin, canagliflozin, dapagliflozin, or ertugliflozin; (2) a DPP-4 inhibitor, such as sitagliptin, vildagliptin, saxagliptin, linagliptin, or alogliptin; (3) an insulin or insulin analog (e.g., insulin icodec); (4) GIP, glucose-dependent insulinotropic polypeptide; and / or (5) an amylin or amylin analog. In some embodiments, the one or more other therapeutic agents may also include (1) a biguanide; (2) a thiazolidinedione; (3) a DPP-4 inhibitor; (4) PYY; and (5) a sulfonylurea. In some embodiments, the one or more other therapeutic agents can include one or more selected from biguanides, sulfonylureas and meglitinides, thiazolidinediones, alpha-glucosidase inhibitors, other glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP4) inhibitors, amylin analogs, sodium-glucose cotransporter 2 (SGLT-2) inhibitors, dopamine agonists, and bile acid sequestrants.In some embodiments, the one or more other therapeutic agents can include one or more selected from the following: metformin, glipizide, gliclazide, glyburide, glimepiride, nateglinide, repaglinide, pioglitazone, rosiglitazone, acarbose, miglitol, voglibose, exenatide, liraglutide, lixisenatide, dulaglutide, albiglutide, sitagliptin, vildagliptin, saxagliptin, linagliptin, gemigliptin, anagliptin, teneligliptin, alogliptin, trelagliptin, omarigliptin, evogliptin, gosogliptin, pramlintide, canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, bromocriptine, and colesevelam.
[0026] In some embodiments, the pharmaceutical compositions herein may include semaglutide as one therapeutic agent in combination with one or more other therapeutic agents useful in the treatment of neurological disorders, such as Alzheimer's disease. For example, in some embodiments, the pharmaceutical compositions herein may include semaglutide as one therapeutic agent in combination with (1) a cholinesterase inhibitor (e.g., Aricept, Exelon, Razadyne), (2) a glutamate regulator (e.g., Namenda), and / or (3) an orexin receptor antagonist (e.g., Belsomra). Fatty acids of formula I.
[0027] Typically, the pharmaceutical compositions herein comprise a fatty acid of formula I: RCOOH, where R represents an aliphatic group, or a pharma- ceutically acceptable salt thereof.
[0028] Useful fatty acids are not particularly limited. For example, in some embodiments, the fatty acid has the formula I: RCOOH, where R represents an alkyl group having 1 to 30 carbon atoms. The alkyl group can be a straight or branched chain alkyl group. For example, in some embodiments, R in formula I is -(CH2) 1~18In some embodiments, R of formula I can be an alkyl group having 3 to 20 carbon atoms. In some embodiments, R of formula I can be an alkyl group having 5 to 16 carbon atoms. In some embodiments, the fatty acid of formula I is a straight chain fatty acid having 2 to 20 carbon atoms, such as caprylic acid, capric acid, or lauric acid. In any embodiment described herein, unless otherwise specified or contrary to context, the fatty acid of formula I can be capric acid.
[0029] The fatty acid of formula I can be present in the pharmaceutical composition herein as a free acid or any pharma- ceutically acceptable salt thereof, such as its alkali or alkaline salt, such as sodium or potassium salt.In some preferred embodiments, the pharmaceutical composition herein comprises sodium caprate.The compound of formula II.
[0030] Typically, the pharmaceutical compositions herein comprise a compound of formula II: [ka] or a pharma- ceutically acceptable salt thereof, wherein the variables are defined herein.
[0031] In some embodiments, the compound of formula II has a G 1 It has no substituents, that is, n is 0.
[0032] In some embodiments, the compound of formula II has one G substituted on the phenyl ring. 1 i.e., n is 1. In some embodiments, in formula II, n is 1 and G 1 is halogen, C1-4 alkyl, or C1-4 alkoxy. In some embodiments, in Formula II, n is 1 and G 1 In some embodiments, in formula II, n is 1 and G 1 is OCH3.
[0033] L in Formula II1 is usually substituted or unsubstituted C2-C 16 For example, in some embodiments, L 1 is unsubstituted C3-C 15 In some embodiments, L is alkylene. 1 is unsubstituted C5-C 13 Alkylene may be linear or branched alkylene. For example, in some embodiments, L 1 is an unsubstituted linear C5-C9 alkylene.
[0034] In some preferred embodiments, the compound of formula II is [ka] It may be, which has the chemical name of 8-(2-hydroxybenzamido)octanoic acid (ChemDraw Software, version 20.0). In a preferred embodiment, the pharmaceutical composition of the present invention comprises a salt of 8-(2-hydroxybenzamido)octanoic acid (preferably the sodium salt), which can be prepared using the methods described, for example, in WO96 / 030036, WO00 / 046182, WO01 / 092206 or WO2008 / 028859. The salt of 8-(2-hydroxybenzamido)octanoic acid (alternatively known as N-(8-(2-hydroxybenzoyl)amino)caprylic acid) can be crystalline and / or amorphous. In some embodiments, the delivery agent comprises an anhydrate, monohydrate, dihydrate, trihydrate, solvate, or trihydrate of a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, as well as combinations thereof. In some embodiments, the pharmaceutical compositions herein comprise salts of N-(8-(2-hydroxybenzoyl)amino)caprylic acid as described in WO2007 / 121318.
[0035] In a more preferred embodiment, the pharmaceutical composition comprises sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (referred to herein as "SNAC").
[0036] In some preferred embodiments, the compound of formula II is [ka] It may be, which has the chemical name 8-(5-chloro-hydroxybenzamido)octanoic acid (ChemDraw Software, version 20.0). In some embodiments, the pharmaceutical compositions of the invention comprise a salt of 8-(5-chloro-2-hydroxybenzamido)octanoic acid.
[0037] In some embodiments, the compound of formula II is [ka] which has the chemical name 10-((2-hydroxybenzoyl)amino)decanoic acid. In some embodiments, the pharmaceutical compositions herein include a salt of 10-((2-hydroxybenzoyl)amino)decanoic acid, such as sodium 10-((2-hydroxybenzoyl)amino)decanoate.
[0038] In some embodiments, the compound of formula II is [ka] It may be, which has the chemical name N-(4-chlorosalicyloyl)-4-aminobutyric acid. In some embodiments, the pharmaceutical compositions herein include a salt of N-(4-chlorosalicyloyl)-4-aminobutyric acid, such as sodium N-(4-chlorosalicyloyl)-4-aminobutyrate.
[0039] In some embodiments, the compound of formula II is [ka] It may be, which has the chemical name N-[8-(2-hydroxy-4-methoxy)benzoyl]aminocaprylic acid. In some embodiments, the pharmaceutical compositions herein include a salt of N-[8-(2-hydroxy-4-methoxy)benzoyl]aminocaprylic acid, such as sodium N-[8-(2-hydroxy-4-methoxy)benzoyl]aminocaprylate.
[0040] The combination of a therapeutic agent, a fatty acid of formula I, and a compound of formula II is not particularly limited.
[0041] In some preferred embodiments, the pharmaceutical compositions herein comprise (a) a polypeptide (e.g., any of those described herein, such as semaglutide), (b) capric acid or a pharma- ceutical acceptable salt thereof, and (c) a compound of formula II or a pharma- ceutical acceptable salt thereof.
[0042] In some preferred embodiments, the pharmaceutical compositions herein comprise (a) a polypeptide (e.g., any of those described herein, such as semaglutide), (b) a straight chain fatty acid having 2 to 20 carbons, such as caprylic acid, capric acid or lauric acid, or a pharma- ceutical acceptable salt thereof, and (c) SNAC.
[0043] In some preferred embodiments, the pharmaceutical compositions herein comprise (a) a polypeptide (e.g., any of those described herein, such as semaglutide), (b) capric acid or a pharma- ceutical acceptable salt thereof, and (c) 8-(2-hydroxybenzamido)octanoic acid or a pharma- ceutical acceptable salt thereof.
[0044] In some preferred embodiments, the pharmaceutical compositions herein comprise (a) a polypeptide (e.g., any of those described herein, such as semaglutide), (b) sodium caprate, and (c) SNAC.
[0045] In some preferred embodiments, the pharmaceutical compositions herein comprise (a) semaglutide, (b) sodium caprate, and (c) SNAC.
[0046] Typically, in the pharmaceutical compositions herein, the weight ratio of (b) the fatty acid of formula I or a pharma- ceutically acceptable salt thereof to (c) the compound of formula II or a pharma- ceutically acceptable salt thereof, (b) / (c), if applicable, is in the range of about 20:1 to about 1:20, such as 5:1 to 1:5, such as about 3:1, about 2:1, about 1:1, about 1:1.5, about 1:2, about 1:2.5 or about 1:3, or any range between the recited values, such as about 1:2. For example, in some embodiments, the pharmaceutical compositions herein comprise (a) semaglutide, (b) sodium caprate, and (c) SNAC, and the weight ratio of sodium caprate to SNAC is about 5:1 to about 1:5, such as about 3:1, about 2:1, about 1:1, about 1:1.5, about 1:2, about 1:2.5 or about 1:3, or any range between the recited values.
[0047] Typically, for each unit dosage form, the total amount of (b) the fatty acid of formula I or a pharma- ceutically acceptable salt thereof and (c) the compound of formula II or a pharma- ceutically acceptable salt thereof ranges from about 100 mg to about 900 mg, e.g., about 300 mg, about 450 mg, about 600 mg, about 750 mg, or about 900 mg, or any range or value between the recited values. For example, in some embodiments, a unit dosage form of a pharmaceutical composition herein, such as a tablet or capsule, can contain (a) a polypeptide (e.g., any of those described herein, such as semaglutide), (b) sodium caprate, and (c) SNAC, wherein the total amount of sodium caprate and SNAC ranges from about 300 to 600 mg, e.g., about 450 mg. The amount of therapeutic agent (e.g., a polypeptide described herein, such as semaglutide) in each unit dosage form is not particularly limited, and for example, typically the therapeutic agent can be in an amount of about 1 mg to about 200 mg (e.g., about 10 mg, about 50 mg, about 100 mg, or any range between the recited values).
[0048] In some embodiments, the pharmaceutical composition comprises a fatty acid of formula I or a pharma- ceutically acceptable salt thereof in an amount of about 50 mg to about 300 mg per unit dose, for example, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 300 mg per unit dose, or any range between the recited values. As used herein, unless otherwise specified or clearly contrary from the context, the weight of a fatty acid of formula I or a pharma- ceutically acceptable salt thereof should be understood as the equivalent weight expressed as the weight of the free acid. However, when a specific reference is made to the amount of sodium caprate, the amount should be understood as the weight of the sodium salt itself, and not the corresponding equivalent weight of capric acid. In some embodiments, the pharmaceutical composition comprises a fatty acid of formula I or a pharma- ceutically acceptable salt thereof in an amount selected from the group consisting of at least 0.6 mmol (millimoles) per unit dose, e.g., at least 0.65 mmol, at least 0.7 mmol, at least 0.75 mmol, at least 0.8 mmol, at least 0.8 mmol, at least 0.9 mmol, at least 0.95 mmol, and at least 1 mmol. In some embodiments, the pharmaceutical composition comprises a fatty acid of formula I or a pharma- ceutically acceptable salt thereof in an amount of 0.6 mmol to 2 mmol, e.g., 0.8 mmol to 1.3 mmol, 0.9 mmol to 1.1 mmol, e.g., 0.95 mmol, 1.0 mmol, etc., per unit dose.
[0049] In some embodiments, the pharmaceutical composition comprises a compound of formula II or a pharma- ceutically acceptable salt thereof in an amount of about 200 mg to about 400 mg per unit dose, for example, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg per unit dose, or any range between the recited values. As used herein, unless otherwise specified or clearly contrary from the context, the weight of a compound of formula II or a pharma- ceutically acceptable salt thereof should be understood as the equivalent weight expressed as the weight of the compound of formula II. However, when a specific reference is made to the amount of SNAC, the amount should be understood as the weight of the sodium salt itself, and not the corresponding equivalent weight of the acid. In some embodiments, the pharmaceutical composition comprises a compound of formula II or a pharma- ceutically acceptable salt thereof in an amount selected from the group consisting of at least 0.6 mmol, e.g., at least 0.65 mmol, at least 0.7 mmol, at least 0.75 mmol, at least 0.8 mmol, at least 0.85 mmol, at least 0.9 mmol, at least 0.95 mmol, and at least 1 mmol per unit dose. In some embodiments, the pharmaceutical composition comprises a compound of formula II or a pharma- ceutically acceptable salt thereof in an amount of 0.6 mmol to 2 mmol, e.g., 0.8 mmol to 1.3 mmol, 0.9 mmol to 1.1 mmol, e.g., 1 mmol per unit dose.
[0050] Typically, the pharmaceutical composition comprises a synergistic combination of (b) a fatty acid of formula I, or a pharma- ceutically acceptable salt thereof, and (c) a compound of formula II, or a pharma- ceutically acceptable salt thereof, for enhancing oral delivery of a therapeutic agent, such as a polypeptide.
[0051] In some particular embodiments, the pharmaceutical composition comprises (a) a therapeutic agent (e.g., any of those described herein), (b) sodium caprate in an amount of about 50 mg to about 300 mg (e.g., about 100 mg, about 150 mg, about 200 mg, or any range between the recited values), and (c) SNAC in an amount of about 200 mg to about 400 mg (e.g., about 200 mg, about 300 mg, about 400 mg, or any range between the recited values). The amount of the therapeutic agent is not particularly limited, and for example, typically the therapeutic agent can be in an amount of about 1 mg to about 200 mg (e.g., about 10 mg, about 50 mg, about 100 mg, or any range between the recited values).
[0052] In some particular embodiments, the pharmaceutical composition comprises: (a) a therapeutic agent (e.g., any of those described herein); (b) sodium caprate in an amount of about 0.6 mmol to 2 mmol (e.g., 0.6 mmol, 0.8 mmol, 0.9 mmol, 1 mmol, 1.1 mmol, 1.3 mmol, 2 mmol, or any range between the recited values, e.g., 0.9 mmol to 1.1 mmol); and (c) SNAC in an amount of 0.6 mmol to 2 mmol (e.g., 0.6 mmol, 0.8 mmol, 0.9 mmol, 1 mmol, 1.1 mmol, 1.3 mmol, 2 mmol, or any range between the recited values, e.g., 0.9 mmol to 1.3 mmol). The amount of the therapeutic agent is not particularly limited, for example, typically the therapeutic agent can be in an amount of about 1 mg to about 200 mg (e.g., about 10 mg, about 50 mg, about 100 mg, or any range between the recited values) or 0.1 μmol to about 2 μmol.
[0053] In some particular embodiments, the pharmaceutical composition comprises (a) a polypeptide (e.g., any of those described herein), (b) sodium caprate in an amount of about 50 mg to about 300 mg (e.g., about 100 mg, about 150 mg, about 200 mg, or any range between the recited values), and (c) SNAC in an amount of about 200 mg to about 400 mg (e.g., about 200 mg, about 300 mg, about 400 mg, or any range between the recited values). The amount of the polypeptide is not particularly limited, and for example, typically the polypeptide can be in an amount of about 1 mg to about 200 mg (e.g., about 10 mg, about 50 mg, about 100 mg, or any range between the recited values).
[0054] In some particular embodiments, the pharmaceutical composition comprises (a) a polypeptide (e.g., any of those described herein), (b) sodium caprate in an amount of about 0.6 mmol to 2 mmol (e.g., 0.6 mmol, 0.8 mmol, 0.9 mmol, 1 mmol, 1.1 mmol, 1.3 mmol, 2 mmol, or any range between the recited values, e.g., 0.9 mmol to 1.1 mmol), and (c) SNAC in an amount of 0.6 mmol to 2 mmol (e.g., 0.6 mmol, 0.8 mmol, 0.9 mmol, 1 mmol, 1.1 mmol, 1.3 mmol, 2 mmol, or any range between the recited values, e.g., 0.9 mmol to 1.3 mmol). The amount of the polypeptide is not particularly limited, and for example, typically the polypeptide can be in an amount of about 1 mg to about 200 mg (e.g., about 10 mg, about 50 mg, about 100 mg, or any range between the recited values).
[0055] In some particular embodiments, the pharmaceutical composition comprises (a) a GLP-1 agonist (e.g., any of those described herein), (b) sodium caprate in an amount of about 50 mg to about 300 mg (e.g., about 100 mg, about 150 mg, about 200 mg, or any range between the recited values), and (c) SNAC in an amount of about 200 mg to about 400 mg (e.g., about 200 mg, about 300 mg, about 400 mg, or any range between the recited values). The amount of the GLP-1 agonist is not particularly limited, and for example, typically, the GLP-1 agonist can be in an amount of about 1 mg to about 200 mg (e.g., about 10 mg, about 50 mg, about 100 mg, or any range between the recited values).
[0056] In some particular embodiments, the pharmaceutical composition comprises: (a) a GLP-1 agonist (e.g., any of those described herein); (b) sodium caprate in an amount of about 0.6 mmol to 2 mmol (e.g., 0.6 mmol, 0.8 mmol, 0.9 mmol, 1 mmol, 1.1 mmol, 1.3 mmol, 2 mmol, or any range between the recited values, e.g., 0.9 mmol to 1.1 mmol); and (c) SNAC in an amount of 0.6 mmol to 2 mmol (e.g., 0.6 mmol, 0.8 mmol, 0.9 mmol, 1 mmol, 1.1 mmol, 1.3 mmol, 2 mmol, or any range between the recited values, e.g., 0.9 mmol to 1.3 mmol). The amount of the GLP-1 agonist is not particularly limited, and for example, typically, the GLP-1 agonist can be in an amount of about 1 mg to about 200 mg (e.g., about 10 mg, about 50 mg, about 100 mg, or any range between the recited values).
[0057] In some specific embodiments, the pharmaceutical composition comprises (a) semaglutide, (b) sodium caprate in an amount of about 50 mg to about 300 mg (e.g., about 100 mg, about 150 mg, about 200 mg, or any range between the recited values), and (c) SNAC in an amount of about 200 mg to about 400 mg (e.g., about 200 mg, about 300 mg, about 400 mg, or any range between the recited values). The amount of semaglutide is not particularly limited, and for example, typically, semaglutide can be in an amount of about 1 mg to about 200 mg (e.g., about 10 mg, about 50 mg, about 100 mg, or any range between the recited values). In some embodiments, semaglutide can be in an amount of about 0.1 μmol to about 2.5 μmol, for example, about 0.5 μmol to about 2.5 μmol.
[0058] In some specific embodiments, the pharmaceutical composition comprises (a) semaglutide, (b) sodium caprate in an amount of about 0.6 mmol to 2 mmol (e.g., 0.6 mmol, 0.8 mmol, 0.9 mmol, 1 mmol, 1.1 mmol, 1.3 mmol, 2 mmol, or any range between the recited values, e.g., 0.9 mmol to 1.1 mmol), and (c) SNAC in an amount of 0.6 mmol to 2 mmol (e.g., 0.6 mmol, 0.8 mmol, 0.9 mmol, 1 mmol, 1.1 mmol, 1.3 mmol, 2 mmol, or any range between the recited values, e.g., 0.9 mmol to 1.3 mmol). The amount of semaglutide is not particularly limited, and for example, typically, semaglutide can be in an amount of about 1 mg to about 200 mg (e.g., about 10 mg, about 50 mg, about 100 mg, or any range between the recited values). In some embodiments, semaglutide may be in an amount of about 0.1 μmol to about 2.5 μmol, for example, about 0.5 μmol to about 2.5 μmol.
[0059] In any embodiment described herein, unless otherwise specified or contrary to the context, the pharmaceutical composition may be in the form of a solid oral dosage form. For example, the pharmaceutical composition herein may typically be a capsule or tablet. In some embodiments, the pharmaceutical composition herein may be provided in discrete units (referred to herein as "unit dosage forms" or "dosage forms"), such as capsules, pills, cachets, lozenges, or tablets, each containing a predetermined amount of active compound(s). In any embodiment described herein, unless otherwise specified or contrary to the context, the pharmaceutical composition may be in unit dosage form. For clarity, the pharmaceutical composition herein may comprise one or more dosage units. For example, the pharmaceutical composition herein is typically a capsule or tablet, with each capsule or tablet constituting a dosage unit. As used herein, each "unit dose" of the pharmaceutical composition refers to a dose of the pharmaceutical composition in each administration, which may comprise one or more unit dosage forms or dosage units. When multiple dosage units are used to fill a unit dose, the dosage units may be the same or different. In a preferred embodiment, each unit dose comprises a single dosage unit.
[0060] The pharmaceutical compositions herein may optionally include one or more additional excipients, such as those suitable for oral administration. For example, in some embodiments, the pharmaceutical compositions include at least one pharma- ceutically acceptable excipient. The term "excipient" as used herein broadly refers to any ingredient other than the active therapeutic ingredient(s). An excipient may be an inert substance, an inactive substance, and / or a non-pharmaceutical active substance. Excipients may serve various purposes, for example, as carriers, vehicles, fillers, binders, lubricants, glidants, disintegrants, flow control agents, crystallization retarders, solubilizers, stabilizers, colorants, flavoring agents, surfactants, enzyme inhibitors, basifying agents, acidifying agents, emulsifiers, and / or tablet coating agents to control the dissolution rate of the solid dosage form according to the pH in the GI tract to improve administration and / or absorption of the active agent. One of ordinary skill in the art can select one or more of the aforementioned excipients with respect to the particular desired properties of the solid oral dosage form by routine experimentation and without undue burden. The amount of each excipient used may vary within the ranges conventional in the art. Techniques and excipients that can be used to formulate oral dosage forms are described in Handbook of Pharmaceutical Excipients, 6th edition, Rowe et al., Eds., American Pharmaceuticals Association and the Pharmaceutical Press, publications department of the Royal Pharmaceutical Society of Great Britain (2009);and Remington: the Science and Practice of Pharmacy, 21st edition, Gennaro, Ed., Lippincott Williams & Wilkins (2005).In some embodiments, the excipients may be selected from binders such as polyvinylpyrrolidone (povidone); fillers such as cellulose powder, microcrystalline cellulose, cellulose derivatives (e.g., hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and hydroxy-propylmethylcellulose), dibasic calcium phosphate, corn starch, pregelatinized starch; lubricants and / or glidants such as stearic acid, magnesium stearate, sodium stearyl fumarate, glycerol tribehenate; flow control agents such as colloidal silica, talc; crystallization retarders such as povidone; solubilizers such as pluronics, povidone; colorants including dyes and pigments such as iron oxide red or yellow, titanium dioxide, talc; pH adjusters such as citric acid, tartaric acid, fumaric acid, sodium citrate, dibasic calcium phosphate, dibasic sodium phosphate; surfactants and emulsifiers such as pluronics, polyethylene glycol, sodium carboxymethylcellulose, polyethoxylated and hydrogenated castor oil; and mixtures of two or more of these excipients and / or adjuvants.
[0061] In some embodiments, the pharmaceutical compositions herein may include lubricants, binders, fillers, and / or chelating agents (e.g., ethylenediaminetetraacetate (EDTA)). However, in some embodiments, the pharmaceutical compositions herein may also be lubricant-free or substantially lubricant-free, such as having less than 0.1%, less than 0.05%, less than 0.01%, or an undetectable amount of lubricant by weight. In some embodiments, the pharmaceutical compositions herein may be magnesium stearate-free. In some embodiments, the pharmaceutical compositions herein may also be binder-free or substantially binder-free, such as having less than 0.1%, less than 0.05%, less than 0.01%, or an undetectable amount of binder by weight. In some embodiments, the pharmaceutical compositions herein may also be filler-free or substantially filler-free, such as having less than 0.1%, less than 0.05%, less than 0.01%, or an undetectable amount of filler by weight. In some embodiments, the pharmaceutical compositions herein can also be free of chelating agents or substantially free of chelating agents, such as having less than 0.1% by weight, less than 0.05% by weight, less than 0.01% by weight, or an undetectable amount of chelating agents.
[0062] In some embodiments, the pharmaceutical composition is in the form of a unit dosage form.
[0063] Preparation method Pharmaceutical compositions can be prepared by those skilled in the art in view of the present disclosure.In some preferred embodiments, the preparation method can include lyophilizing the therapeutic agent, the fatty acid of formula I as described herein or its pharmaceutical acceptable salt, and the compound of formula II as described herein or its pharmaceutical acceptable salt, which can be beneficial for achieving a superior PK profile compared to simply blending these components, as shown in the examples section.
[0064] In some embodiments, the disclosure also provides a method of preparing a pharmaceutical composition comprising a Therapeutic Agent, the method comprising: (a) mixing a Therapeutic Agent (e.g., any described herein, such as a polypeptide described herein, with a compound of formula II as described herein, or a pharma- ceutically acceptable salt thereof, and a fatty acid of formula I as described herein, or a pharma- ceutically acceptable salt thereof, to form a mixture; (b) lyophilizing the mixture formed in (a) to form a lyophilized mixture; and, optionally, (c) mixing the lyophilized mixture with a pharma- ceutically acceptable excipient.
[0065] In some embodiments, the therapeutic agent is first mixed with a compound of formula II described herein, or a pharma- ceutically acceptable salt thereof, followed by the addition of a fatty acid of formula I described herein, or a pharma- ceutically acceptable salt thereof, to form a mixture.
[0066] In some embodiments, the disclosure also provides a method of preparing a composition comprising a polypeptide (e.g., any of those described herein, such as semaglutide), the method comprising: (a) coupling a polypeptide to a compound of formula II: [ka] or a pharma- ceutically acceptable salt thereof, 1 are independently OH, NH2, NH(C 1~4 alkyl), N(C 1~4 Alkyl)(C 1~4 Alkyl), halogen (e.g., Cl), C 1~4 Alkyl, or C 1~4 Alkoxy (e.g., OCH3), L 1 is a substituted or unsubstituted C2-C 16 Alkylene, or substituted or unsubstituted C2-C 16 alkenylene); (b) lyophilizing the mixture formed in (a).
[0067] In some embodiments, the mixing in (a) further comprises mixing the polypeptide, the compound of formula II or a pharma- ceutically acceptable salt thereof, and a fatty acid of formula I:RCOOH or a pharma- ceutically acceptable salt thereof, where R represents an aliphatic group. In some embodiments, the fatty acid of formula I is a straight chain fatty acid having 2 to 20 carbon atoms, such as caprylic acid, capric acid, or lauric acid. In some embodiments, the weight ratio of (i) the fatty acid of formula I or a pharma- ceutically acceptable salt thereof to (ii) the compound of formula II or a pharma- ceutically acceptable salt thereof, (i) / (ii), is in the range of about 20:1 to about 1:20, e.g., about 5:1 to 1:5, e.g., about 3:1, about 2:1, about 1:1, about 1:1.5, about 1:2, about 1:2.5, or about 1:3, or any range between the recited values, e.g., about 1:2. In some embodiments, the fatty acid of formula I or a pharma- ceutically acceptable salt thereof is in an amount of about 50 mg to about 300 mg. In some embodiments, the compound of formula II or a pharma- ceutically acceptable salt thereof is in an amount of about 200 mg to about 400 mg.
[0068] In some particular embodiments, where applicable, in the above methods, (a) the therapeutic agent (e.g., any of those described herein) is in an amount of about 1 mg to about 200 mg (e.g., about 10 mg, about 50 mg, about 100 mg, or any range between the recited values), (b) the fatty acid of formula I or a pharmaceutically acceptable salt thereof is sodium caprate in an amount of about 50 mg to about 300 mg (e.g., about 100 mg, about 150 mg, about 200 mg, or any range between the recited values), and / or (c) the compound of formula II or a pharmaceutically acceptable salt thereof is SNAC in an amount of about 200 mg to about 400 mg (e.g., about 200 mg, about 300 mg, about 400 mg, or any range between the recited values).
[0069] In some particular embodiments, where applicable, in the above methods, (a) the therapeutic agent (e.g., any of those described herein) is in an amount of about 1 mg to about 200 mg (e.g., about 10 mg, about 50 mg, about 100 mg, or any range between the recited values); (b) the fatty acid of formula I or a pharmaceutically acceptable salt thereof is sodium caprate in an amount of about 0.6 mmol to about 2 mmol (e.g., 0.6 mmol, 0.8 mmol, 0.9 mmol, 1 mmol, 1.1 mmol, 1.3 mmol, 2 mmol, or any range between the recited values, e.g., 0.9 to 1.3 mmol).
[0070] In some particular embodiments, where applicable, in the above methods, (a) the therapeutic agent (e.g., any of those described herein) is a polypeptide described herein in an amount of, for example, about 1 mg to about 200 mg (e.g., about 10 mg, about 50 mg, about 100 mg, or any range between the recited values); (b) the fatty acid of formula I or a pharmaceutically acceptable salt thereof is sodium caprate in an amount of about 50 mg to about 300 mg (e.g., about 100 mg, about 150 mg, about 200 mg, or any range between the recited values); and / or (c) the compound of formula II or a pharmaceutically acceptable salt thereof is SNAC in an amount of about 200 mg to about 400 mg (e.g., about 200 mg, about 300 mg, about 400 mg, or any range between the recited values).
[0071] In some particular embodiments, where applicable, in the above methods, (a) the therapeutic agent (e.g., any of those described herein) is a polypeptide described herein in an amount of, for example, about 1 mg to about 200 mg (e.g., about 10 mg, about 50 mg, about 100 mg, or any range between the recited values), and (b) the fatty acid of formula I or a pharma- ceutically acceptable salt thereof is in an amount of, for example, about 0.6 mmol to about 2 mmol (e.g., 0.6 mmol, 0.8 mmol, 0.9 mmol, 1 mmol, 1.1 mmol, 2.0 mmol, 2.5 mmol, 3.0 mmol, 4.0 mmol, 5.0 mmol, 6.0 mmol, 7.0 mmol, 8.0 mmol, 9.0 mmol, 10.0 mmol, 11.0 mmol, 12.0 mmol, 13.0 mmol, 14.0 mmol, 15.0 mmol, 16.0 mmol, 17.0 mmol, 18.0 mmol, 19.0 mmol, 20.0 mmol, 21.0 mmol, 22.0 mmol, 23.0 mmol, 24.0 mmol, 25.0 mmol, 26.0 mmol, 27.0 mmol, 28.0 mmol, 29.0 mmol, 30.0 mmol, 31.0 mmol, 32.0 mmol, 33.0 mmol, 34.0 mmol, 35.0 mmol, 36.0 mmol, 37.0 mmol, 38.0 mmol, 39.0 mmol, 40.0 mmol, 41.0 mmol, 42.0 mmol, 43.0 mmol, 44.0 mmol, 45.0 mmol, 46.0 mmol, 47.0 mmol, 48.0 mmol, 49.0 mmol, 50.0 mmol, 50 and / or (c) the compound of formula II or a pharma- ceutically acceptable salt thereof is SNAC in an amount of 0.6 mmol to 2 mmol (e.g., 0.6 mmol, 0.8 mmol, 0.9 mmol, 1 mmol, 1.1 mmol, 1.3 mmol, 2 mmol, or any range between the recited values, e.g., 0.9 to 1.3 mmol).
[0072] In some particular embodiments, where applicable, in the above methods, (a) the therapeutic agent is, for example, a GLP-1 agonist (e.g., any of those described herein) in an amount of about 1 mg to about 200 mg (e.g., about 10 mg, about 50 mg, about 100 mg, or any range between the recited values); (b) the fatty acid of formula I or a pharmaceutically acceptable salt thereof is sodium caprate in an amount of about 50 mg to about 300 mg (e.g., about 100 mg, about 150 mg, about 200 mg, or any range between the recited values); and / or (c) the compound of formula II or a pharmaceutically acceptable salt thereof is SNAC in an amount of about 200 mg to about 400 mg (e.g., about 200 mg, about 300 mg, about 400 mg, or any range between the recited values).
[0073] In some particular embodiments, where applicable, in the above methods, (a) the therapeutic agent is a GLP-1 agonist (e.g., any of those described herein) in an amount of, for example, about 1 mg to about 200 mg (e.g., about 10 mg, about 50 mg, about 100 mg, or any range between the recited values), and (b) the fatty acid of formula I or a pharma- ceutically acceptable salt thereof is in an amount of about 0.6 mmol to about 2 mmol (e.g., 0.6 mmol, 0.8 mmol, 0.9 mmol, 1 mmol, ol, 1.1 mmol, 1.3 mmol, 2 mmol, or any ranges between the recited values), and / or (c) the compound of formula II or a pharma- ceutically acceptable salt thereof is SNAC in an amount of 0.6 mmol to 2 mmol (e.g., 0.6 mmol, 0.8 mmol, 0.9 mmol, 1 mmol, 1.1 mmol, 1.3 mmol, 2 mmol, or any ranges between the recited values, e.g., 0.9 to 1.3 mmol).
[0074] In some particular embodiments, where applicable, in the above methods, (a) the therapeutic agent is semaglutide in an amount of about 1 mg to about 200 mg (e.g., about 10 mg, about 50 mg, about 100 mg, or any range between the recited values), or in an amount of about 0.1 μmol to about 2.5 μmol, e.g., about 0.5 μmol to about 2.5 μmol; (b) the fatty acid of formula I or a pharmaceutically acceptable salt thereof is sodium caprate in an amount of about 50 mg to about 300 mg (e.g., about 100 mg, about 150 mg, about 200 mg, or any range between the recited values); and / or (c) the compound of formula II or a pharmaceutically acceptable salt thereof is SNAC in an amount of about 200 mg to about 400 mg (e.g., about 200 mg, about 300 mg, about 400 mg, or any range between the recited values).
[0075] In some particular embodiments, where applicable, in the above methods, (a) the therapeutic agent is semaglutide in an amount of, for example, about 1 mg to about 200 mg (e.g., about 10 mg, about 50 mg, about 100 mg, or any range between the recited values), or in an amount of about 0.1 μmol to about 2.5 μmol, for example, about 0.5 μmol to about 2.5 μmol; and (b) the fatty acid of formula I or a pharma- ceutical acceptable salt thereof is, for example, about 0.6 mmol to about 2 mmol (e.g., 0.6 mmol, 0.8 mmol, , 0.9 mmol, 1 mmol, 1.1 mmol, 1.3 mmol, 2 mmol, or any range between the recited values), and / or (c) the compound of formula II or a pharma- ceutically acceptable salt thereof is SNAC in an amount of 0.6 mmol to 2 mmol (e.g., 0.6 mmol, 0.8 mmol, 0.9 mmol, 1 mmol, 1.1 mmol, 1.3 mmol, 2 mmol, or any range between the recited values, e.g., 0.9 to 1.3 mmol).
[0076] Compositions containing a therapeutic agent prepared by the methods herein are also novel compositions of the disclosure.
[0077] In some embodiments, the disclosure further provides a method for preparing a pharmaceutical composition comprising mixing a composition comprising a therapeutic agent prepared by a method herein with a pharma- ceutically acceptable excipient (e.g., any of those described herein).
[0078] Treatment method The pharmaceutical compositions described herein are useful for treating a disease or disorder in a subject in need thereof, which may be any disease or disorder known to be treatable with the therapeutic agents disclosed herein. Enhanced oral delivery of therapeutic agents as shown in the present disclosure may provide an advantageous alternative treatment option using these therapeutic agents.
[0079] For example, in some embodiments, the disclosure provides a method of treating type 2 diabetes or obesity in a subject in need thereof, the method comprising orally administering a pharmaceutical composition described herein to deliver a therapeutically effective amount of a therapeutic agent (e.g., a GLP-1 agonist described herein) to the subject.
[0080] Type 2 diabetes mellitus (T2D) is a serious global public health problem with a significant burden of complications due to micro- and macrovascular disease. Diabetes mellitus development consists of changes in multiple organs and is usually accompanied by elevated blood glucose levels and loss or deterioration of glycemic control. Glycemic control in T2D through various mechanisms of action has been demonstrated to reduce the incidence of microvascular diseases such as diabetic kidney disease and diabetic retinopathy (Chatterjee S, Khunti K, Davies MJ.Type 2 diabetes.Lancet.2017;389(10085):2239-2251).
[0081] Incretins are an important class of drugs for the treatment of diabetes and obesity, including GLP-1, GIP, PYY, etc. GLP-1 receptor agonists have become important and essential drugs that are widely prescribed. GLP-1 is mainly expressed in L cells of the intestinal tract and the brain stem. The GLP-1 receptor (GLP-1 R) is a G protein-coupled receptor that is expressed in various tissues, including pancreatic islets, gastrointestinal tract, lungs, cardiovascular system, kidneys, nodose ganglion neurons of the vagus nerve, hypothalamus and brain stem of the central nervous system (Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide1. Proc Natl Acad Sci USA. 1992; 89(18): 8641-8645.). GLP-1 expressed from intestinal L-cells can circulate and either directly bind to classical receptors in pancreatic islets or indirectly signal to hepatic vagus nerve branches in the portal vein, potentiating glucose-induced and most of the postprandial insulin secretion (Pais R, Gribble FM, Reimann F. Stimulation of incretin secreting cells. Ther Adv Endocrinol Metab. 2016;7(1):24-42.). Signals are sent to the hypothalamus, resulting in decreased appetite, stimulation of gluconeogenesis, decreased hepatic glucose production, amplified glucose-dependent insulin release, inhibited glucagon release, increased cardiac output and cardioprotection, and decreased hypertension (Muller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130.). In T2D, the incretin system is impaired, leading to insufficient GLP-1 production or inhibited GLP-1 action.Therefore, GLP-1 and GLP-1 analogues have been developed as treatments for T2D (Aulinger BA, Vahl TP, Prigeon RL, D'Alessio DA, Elder DA. The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact? Am J Physiol Endocrinol Metab. 2016;310(9):E774-781).
[0082] Natural GLP-1 is rapidly degraded by dipeptidyl peptidase-IV (DPP-IV) with a half-life of approximately less than 2 minutes. Thus, many GLP-1 receptor agonist analogs (GLP-1 RAs) have been developed in an attempt to extend the half-life. Such GLP-1 analogs include exendin-4, liraglutide, dulaglutide, lixisenatide, and semaglutide, which are approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes. Exendin-4 is a 53% homologous peptide extracted from the venom of the Gila monster. It is resistant to degradation by DPP4. Structural modifications, such as the substitution of certain amino acids and / or the addition of certain fatty acids, have extended the half-life and enabled the daily to once-weekly administration of GLP-1 analogues, including dulaglutide, albiglutide, liraglutide, lixisenatide, and semaglutide (Romera I, Cebria'n-Cuenca A, A'lvarez-Guisasola F, Gomez-Peralta F, Reviriego JA review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes.Diabetes Ther.2019;10(1):5-19.).
[0083] The class of GLP-1 RAs in T2D has been demonstrated to show favorable effects on weight management with significant reductions in A1C and minimal risk of hypoglycemia (Trujillo JM. Glucagon-like peptide-1 receptor agonists. In: White JR (ed.) Guide to medications for the treatment of diabetes mellitus. Arlington County, VA: American Diabetes Association, 2020, pp. 190-210.). Furthermore, three of the GLP-1 RAs: dulaglutide, liraglutide and semaglutide have demonstrated cardiovascular benefits (Matza LS, Boye KS, Steerward DK, et al. Crossover clinical trial assessing patient preference between the dulaglutide pen and the semaglutide pen (PREFER). Diabetes Met Obes 2020; 22: 355-364). The use of GLP-1 RAs is associated with side effects, mainly GI AEs and injection site-related AEs. The use of GLP-RAs may also be limited by the injection route of administration, which may result in adherence issues. Evaluating head-to-head trials showed that long-acting agents provided greater A1C reductions than short-acting agents, with semaglutide providing the greatest A1C reduction. Among the long-acting agents, exenatide XR appears to have the least effect on A1C, but provides more A1C reduction compared with the short-acting agents. With regard to weight, the distinction between the agents becomes more blurred.Long-acting agents tend to cause more significant weight loss compared to short-acting agents, with semaglutide again taking the lead with the greatest weight loss (Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 2018;6:275-286.) (Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER4): a randomised, double-blind, phase 3a trial. Lancet 2019;394:39-50.). GI side effects appear to be highest with the short-acting agents, as with subcutaneous semaglutide, and lowest with exenatide XR. Injection site reactions are more common, especially with long-acting agents such as exenatide, which is administered once weekly, and can cause small, temporary nodules at the injection site. Patient satisfaction data indicate that patients are more satisfied with weekly injections compared with twice-daily injections. Discontinuation rates due to adverse events vary by agent and study, but are generally low, with less than 10% of patients in studies discontinuing GLP-1 RA therapy due to adverse events (Wilke T, Mueller S, Groth A, et al. Nonpersistence and non-adherence of patients with type2 diabetes mellitus in therapy with GLP-1 receptor agonists: a retrospective analysis. Diabetes Ther 2016;7:105-124.). The risk of hypoglycemia is low with GLP-1 RAs, and rates were similar across all GLP-1 RA treatment groups.Importantly, current guidelines prioritize the use of GLP-1 RAs with proven cardiovascular benefits (dulaglutide, liraglutide, semaglutide) in patients with atherosclerotic CV disease (ASCVD) and at risk for ASCVD, regardless of baseline A1C.
[0084] GLP-1 and GLP-1 analogues are peptides with high molecular weight, very poor permeability through biological membranes, and susceptible to digestive enzyme degradation, so oral delivery of GLP-1 analogues usually results in very poor oral bioavailability. Therefore, all GLP RA treatments are injections, which results in difficulties in use and fear of needles, making treatment acceptance and adherence difficult (Wilke T, Mueller S, Groth A, et al. Nonpersistence and non-adherence of patients with type 2 diabetes mellitus in therapy with GLP-1 receptor agonists: a retrospective analysis. Diabetes Ther 2016; 7: 105-124.).
[0085] The first orally delivered GLP-1 analogue was semaglutide, which was co-formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) (Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318(15):1460-70.290). The mechanism by which SNAC enables oral absorption of semaglutide is still unclear, but tentatively it may involve one or more of the following MOAs: reduction of enzymatic degradation, optimization of the physicochemical properties of the drug for membrane transport, and improvement of fluidity across biological membranes. In the PIONEER study, oral semaglutide co-formulated with SNAC was shown to be effective and safe in hospitalized patients, and the product (Revelsus®) received FDA approval on September 20, 2019 (Bucheit J, Pamulapati LG, Carter N, Malloy K, Dixon DL, Sisson EM. Oral semaglutide: a review of the first oral glucagon-like peptide-1 receptor agonist. Diabetes Technol Ther. 2020;1:10-8). However, although SNAC has been shown to enhance semaglutide absorption, oral bioavailability (BA%) remains very low, approximately 0.5-1% in humans (FDA Clinical Pharmacology Review; https: / / www.accessdata.fda.gov / drugsatfda_docs / nda / 2019 / 213051Orig1s000ClinPharmR.pdf).
[0086] Low bioavailability contributes to large variations in drug exposure in the systemic circulation. Furthermore, low bioavailability can significantly increase costs, which can be prohibitive for payers, especially as higher doses of the drug are required to control obesity. As an example in the case of semaglutide, the injectable version of semaglutide (Ozempic) has a dose of 0.5-1 mg once a week for diabetes control, while a dose of 2.4 mg once a week is required for obesity control (approved by the FDA as Ugovi in 2021). For the oral version of semaglutide (Rebelsus), the daily dose is up to 14 mg (FDA labeling for Rebelsus and Ugovi). The dose of the oral version required for obesity can be up to and in excess of 50 mg. Chemical synthesis or semi-biosynthesis of semaglutide as a modified peptide is costly. Currently, the cost of semaglutide as an active product ingredient (API) is approximately US$0.8 per milligram (mg). Therefore, for Rybelsus 14mg per day for diabetes indication, the COGS (Cost of Goods) is about US$336 per month, which is almost close to the cost of the commercial product (Novo Nodisk's price is US$770 per month) https: / / www.goodrx.com / rybelsus. For potential indications such as obesity, for 50mg per day, the COGS is about US$1,200 per month, which exceeds the price that payers can tolerate. Therefore, it is important and essential to develop an oral formulation of semaglutide that improves BA%, reduces variability, and controls COGS in order to enable the extension of obesity treatment, meet the medical value of GLP-1 therapeutic drugs, contribute to the medical care of T2D and obesity patients, and reduce the financial burden on the medical system.
[0087] As discussed herein, the combination of a fatty acid of formula I and a compound of formula II, or their respective salts, more particularly the combination of sodium caprate and SNAC, significantly improved the oral bioavailability of a GLP-1 agonist, particularly semaglutide, compared to the use of SNAC as an enhancer.Accordingly, the method of the present invention can advantageously use the pharmaceutical composition of the present invention to orally administer a GLP-1 agonist for the treatment of various diseases or disorders in which a GLP-1 agonist may be beneficial, such as type 2 diabetes or obesity.
[0088] Combination therapy The pharmaceutical composition of the present invention can be used as a single therapy or as a combination therapy.For example, in some embodiments, the pharmaceutical composition can be a fixed dose combination of two or more active therapeutic agents.Non-limiting combination therapies contemplated include:
[0089] Combination of GLP-RA inhibitors and SGLT2 inhibitors: Cardiovascular benefits. Sodium-glucose cotransporter (SGLT) proteins function independently of insulin in glucose regulation. Sodium-glucose cotransporter 1 (SGLT1) protein is a high-affinity low-capacity transporter of glucose and is expressed in the small intestine and proximal tubules of the kidney. SGLT1 protein in the proximal tubules of the kidney is responsible for less than 10% of the reabsorption of filtered glucose. Sodium-glucose cotransporter-2 (SGLT2) protein is expressed in the proximal tubules of the kidney and is responsible for approximately 90% of the reabsorption of filtered glucose (Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type2(SGLT2) inhibitors for the treatment of type2 diabetes mellitus.Drugs.2015Jan;75(1):33-59.). There are several SGLT2 selective inhibitors approved by the FDA. These include canagliflozin, dapagliflozin, and empagliflozin. Of the three FDA-approved drugs, empagliflozin has the highest selectivity for SGLT2 compared to SGLT1, and canagliflozin has the lowest selectivity (Shubrook JH, Bokaie BB, Adkins SE. Empagliflozin in the treatment of type 2 diabetes: evidence to date. Drug design, development and therapy. 2015;9:5793-803.). SGLT2 inhibitors have clinically demonstrated weight management and antihypertensive effects. The risk of hypoglycemia with SGLT2 inhibitors is smaller than that with insulin and sulfonylureas. (Desouza CV, Gupta N, Patel A. Cardiometabolic Effects of a New Class of Antidiabetic Agents. Clin Ther. 2015Jun1;37(6):1178-94.).
[0090] Recent studies have demonstrated that GLP-RAs such as dapagliflozin and empagliflozin are not associated with an increased risk of major cardiovascular events. More importantly, studies have demonstrated significant CV benefits with SGLT2 inhibition, including a 38% reduction in the relative risk of cardiovascular death in empagliflozin vs. placebo in T2D patients at high risk for cardiovascular events (Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England journal of medicine. 2015Nov26;373(22):2117-28. This is a pivotal cardiovascular outcomes trial of empagliflozin).
[0091] GLP-1 RA inhibitors and SGLT-2 inhibitors have shown evidence to improve clinical outcomes in diabetic patients with cardiovascular disease. New T2D pharmacotherapy guidelines recommend the use of GLP-1 RAs for the prevention and treatment of obese patients at risk of atherosclerotic cardiovascular disease, whereas SGLT-2i are suggested for patients at risk of chronic heart failure. However, considering that both classes of drugs have different mechanisms in the treatment of T2D and diabetes, there are no systematic studies, especially clinical trials, to further evaluate the potential additive or synergistic effects of these two classes of drugs on CV benefits.
[0092] The main reason why there are no robust clinical studies on the combination of GLP-RAs and SGLT2i may be due to commercial or financial reasons. GLP-RAs are also daily or weekly injectable peptides (except for oral semaglutide), while SGLT2i are all oral tablets administered daily. Such a combination of an injectable and an oral agent may not be accepted by patients in practice, and more importantly, it is not feasible to develop a financially supported combination because of the lack of intellectual property available when directly combining two marketed drugs.
[0093] The only oral GLP-RA on the market is Rybelsus, but its BA% is too low to be economically viable for coadministration. Technically, oral semaglutide is absorbed in the stomach by the carrier SNAC, but SGLTi are formulated into tablets with a coated film, which targets absorption in the small intestine, which has a large absorption surface and is rich in endothelial cell villi, allowing a much higher permeability than in the stomach.
[0094] In some embodiments, the present invention allows for the formulation of GLP-RA and SGLTi in the same tablet, which not only improves the oral bioavailability of GLP-RA compared to formulations containing SNAC alone, but also allows for the absorption of SGLTi from the stomach. Such a fixed dose combination of GLP-RA and SGLTi in one tablet provides significant medical value with convenient use and economic feasibility.
[0095] definition As used herein, the singular forms "a," "an," and "the" include plural references unless expressly stated or clearly clear from the context that this is not intended.
[0096] The term "and / or," when used herein in a phrase such as "A and / or B," is intended to include both A and B, A or B, A (alone), and B (alone). Similarly, the term "and / or," when used herein in a phrase such as "A, B, and / or C," is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0097] Headings and subheadings are used for convenience and / or formal compliance only, do not limit the subject technology, and should not be referenced in connection with interpreting the description of the subject technology. Features described under one heading or one subheading of the subject disclosure may be combined with features described under other headings or subheadings in various embodiments. Moreover, all features under a single heading or a single subheading may not necessarily be used together in an embodiment.
[0098] As used herein, the term "about" modifies quantities related to the present invention, and refers to variations in quantity that may occur, for example, through routine testing and handling, through unintentional errors in such testing and handling, through differences in manufacture, source, or purity of the components used in the present invention, and the like. As used herein, "about" a particular value includes the particular value, for example, about 10% includes 10%. Whether or not modified by the term "about", the claims include the equivalent of the recited amount. In one embodiment, the term "about" means within 20% of the reported numerical value.
[0099] As used herein, the terms "polypeptide" and "peptide" refer to a compound composed of at least five constituent amino acids connected by peptide bonds. The constituent amino acids may be from the group of amino acids encoded by the genetic code, or they may be natural and synthetic amino acids not encoded by the genetic code.
[0100] As used herein, the term "analog" referring to a polypeptide means a modified peptide in which one or more amino acid residues of the peptide have been replaced by other amino acid residues, and / or one or more amino acid residues have been deleted from the peptide, and / or one or more amino acid residues have been deleted from the peptide, and / or one or more amino acid residues have been added to the peptide.
[0101] As used herein, the term "derivative" with respect to a peptide refers to a chemically modified peptide or analog thereof, in which at least one substituent is not present in the unmodified peptide or analog thereof, i.e., the covalently modified peptide. Typical modifications are amides, 20 carbohydrates, alkyl groups, acyl groups, esters, etc. An example of a derivative of GLP-1(7-37) is NE26-((4S)-4-(hexadecanoylamino)-carboxy-butanoyl)[Arg34,Lys26]GLP-1-(7-37).
[0102] In some embodiments, as used herein, the term "GLP-1 analog" refers to a peptide or compound that is a variant of human glucagon-like peptide-1 (GLP-1(7-37)). GLP-1(7-37) has the sequence HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG (SEQ ID NO: 1). In some embodiments, the term "variant" refers to a compound that includes one or more amino acid substitutions, deletions, additions, and / or insertions.
[0103] In some embodiments, the GLP-1 agonist exhibits at least 60%, 65%, 70%, 80% or 90% sequence identity to GLP-1(7-37) over the entire length of GLP-1(7-37). As an example of a method for determining the sequence identity between two analogs, the two peptides [Aib8]GLP-1(7-37) and GLP-1(7-37) are aligned. The sequence identity between [Aib8]GLP-1(7-37) and GLP-1(7-37) is determined by the number of aligned identical residues minus the number of different residues divided by the total number of residues in GLP-1(7-37). Thus, in the above example, the sequence identity is (31-1) / 31.
[0104] As used herein, the term "GLP-1 agonist" refers to a compound that fully or partially activates the human GLP-1 receptor. In some embodiments, the GLP-1 agonist is a GLP-1 analog that optionally contains one substituent. In some embodiments, the GLP-1 agonist is exendin-4, the sequence of which is HGEGTFITSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (SEQ ID NO: 2). In some embodiments, the GLP-1 agonist contains one substituent covalently attached to the peptide. In some embodiments, the substituent contains a fatty acid or a fatty acid diacid. In some embodiments, the substituent contains a C16, C18 or C20 fatty acid. In some embodiments, the substituent contains a C16, C18 or C20 fatty diacid. Examples of GLP-1 RAs include, but are not limited to, semaglutide, liraglutide, dulaglutide, lixisenatide, exenatide, and the like.
[0105] In some embodiments, the GLP-1 agonist is selected from the group consisting of WO93 / 19175, WO96 / 29342, WO98 / 08871, WO99 / 43707, WO99 / 43706, WO99 / 43341, WO99 / 43708, WO2005 / 027978, WO2005 / 058954, WO2005 / 058958, WO2006 / 0 05667, WO2006 / 037810, WO2006 / 037811, WO2006 / 097537, WO2006 / 097538, WO2008 / 023050, WO2009 / 030738, WO2009 / 030771, and WO2009 / 030774.
[0106] In some embodiments, the GLP-1 agonist is selected from the group consisting of N-ε37{2-[2-(2-{2-[2-((R)-3-carboxy-3-{[1-(19-carboxynonadecanoyl)piperidine-4-carbonyl]amino}propionylamino)ethoxy]ethoxy}acetylamino)ethoxy]ethoxy}acetyl[desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1(7-37)amide, N-ε26{2-[2-(2-{2-[2-((R)-3-carboxy-3-{[1-(19-carboxynonadecanoyl)piperazine-4-carbonyl]amino}propionylamino)ethoxy]ethoxy}acetylamino)ethoxy]ethoxy}acetyl[desaminoHis7,A rg34]GLP-1-(7-37), N-ε37{2-[2-(2-{2-[2-((S)-3-carboxy-3-{[1-(19-carboxynonadecanoyl)piperazine-4-carbonyl]amino}propionylamino)ethoxy]ethoxy}acetylamino)ethoxy]ethoxy}acetyl[Aib8,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37)amide, N-ε37-[2-(2-[2-(2-[2-(2-((R)-3-[1-(17-carboxyheptadecanoyl)piperazin-4-ylcarbonylamino]3-carboxypropionylamino)ethoxy)ethoxy]acetylamino)ethoxy]ethoxy]acetyl][,desaminoHis7,Glu22 Arg26,Arg34,Phe(m-CF3)28]GLP-1-(7-37)amide, N-ε26-[(S)-4-carboxy-4-({trans-4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyryl][Aib8,Arg34]GLP-1-(7-37), N-ε26-{4-[(S)-4-carboxy-4-({trans-4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyryl GLP-1-(7-37), N-ε26-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37), N-ε26-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37) ) amide, N-ε37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][Aib8,Glu22,Arg26,Arg34,Lys37]GLP-1-( 7-37) Amido, N-ε37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][desaminoHis7,Glu22,Arg26,Arg34,Lys37 ]GLP-1-(7-37)amide, N-ε37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({4-[(trans-19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][desaminoHis7,Arg26,Arg34,Lys 37]GLP-1-(7-37)amide, N-ε37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37), N-ε26[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl[Aib8,Lys26]GLP-1(7-37)amide, N-ε26 [2-(2-[2-(2-[2-(2-((S)-2-[trans-4-((9-carboxynonadecanoylamino]methyl)cyclohexylcarbonylamino]-4-carboxybutanoylamino)ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Lys26]GLP-1(7-37)amide, N-ε37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19- GLP-1-(7-37), N-ε37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][desaminoHis7,Arg26,Arg34,Lys37] N-ε26-[2-(2-{2-[(S)-4-carboxy-4-{4-[4-(16-(1H-tetrazol-5-yl)-hexadecanoylsulfamoyl)butyrylamino]-butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl] [desaminoHis7,Glu22,Arg26,Glu30,Arg34,Lys37]GLP-1-(7-37), N-ε26-[2-(2-{2-[(S)-4-carboxy-4-{4-[4-(16-(1H-tetrazol-5-yl)-hexadecanoylsulfamoyl)butyrylamino]-butyryl amino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37), N-ε26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{12-[4-(16-(1H-tetrazol-5-yl)hexadecanoyl-sulfamoyl)butyrylamino]dodecanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37), N-ε26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{6-[4-(16-(1H-tetrazol-5-yl)hexadecanoyl-sulfamoyl)butyrylamino]hexanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37), N-ε26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{4-[4-(16-(1H-tetrazol-5-yl)hexadecanoyl-sulfamoyl)butyrylamino]hexanoylamino}butyrylamino]butyrylamino]ethoxy}ethoxy]acetyl] GLP-1-(7-34), N-ε26-[2-(2-{2-[(S)-4-carboxy-4-{12-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]-dodecanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34] rg34]GLP-1-(7-34), N-ε26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{6-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]hexadecanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-34), N-ε26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{12-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]hexadecanoylamino}butyrylamino]ethoxy}ethoxy]acetyl GLP-1-(7-35), N-ε26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{6-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]hexanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]Arg34]GLP-1-(7-35), N-ε26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{6-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]hexanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-36)amide, N-ε26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{6-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]hexanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy]acetyl] H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]hexanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-35), N-ε26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{12-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]dodecanoylamino}butyryl-amino)butyrylamino]ethoxy}ethoxy)acetyl ][Aib8,Lys33,Arg34]GLP-1-(7-34), N-ε26-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{12-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]dodecanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-36)amide, N-ε26-[2-(2-{2-[2-(2-{2-[2-(2-{2-[2-(2-{2-[ 2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{12-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]dodecanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][Aib8,Lys26,Arg34]GLP-1-(7-36)amide, N-ε37-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{12-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]dodecanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37)amide, N-ε37-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{12-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]dodecanoylamino}butyrylamino] butyrylamino]ethoxy}ethoxy)acetyl][desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37)amide, N-ε37{2-[2-(2-{2-[2-((R)-3-carboxy-3-{[1-(19-carboxy-nonadecanoyl)piperidine-4-carbonyl]amino}propionylamino)ethoxy]ethoxy}acetylamino)ethoxy]ethoxy}acetyl[desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1 (7-37) amide, N-ε37-[2-[2-(2-{2-[2-((S)-3-carboxy-3-{[1-(19-carboxynonadecanoyl)piperidine-4-carbonyl]amino}propionylamino)ethoxy]ethoxy}acetylamino)ethoxy]ethoxy}acetyl[Aib8,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37) amide, N-ε37-[2-(2-[2-(2-[2-(2-((R)-3-[1-(17-carboxyheptadecanoyl)piperidine 3-[2-(2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy]ethoxy]acetyl],[2-(2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy]ethoxy]acetyl],[2-(2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy]ethoxy] )acetylamino]ethoxy}ethoxy)acetyl][Aib8,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37)amide, N-ε37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37)amide, N-ε37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl][desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37), N-ε37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl] [(19-carboxy-nonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl]carboxy[desaminoHis7,Glu22,Arg26,Glu30,Arg34,Lys37]GLP-1-(7-37), N-ε37-[2-(2-{2-[(S)-4-carboxy-4-((S)-4-carboxy-4-{12-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]dodecanoylamino}butyric acid GLP-1-(7-37)amide, N-ε37-[2-(2-{2-[(S)-4-carboxy-4-{12-[4-(16-(1H-ttetrazol-5-yl)hexadecanoylsulfamoyl)butyrylamino]dodecanoylamino}butyrylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Glu22,Arg26,Arg34,Lys37]G LP-1-(7-37)amide, N-ε37-(3-((2-(2-(2-(2-(2-(2-hexadecyloxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)propionyl)[desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1(7-37)-amide, N-ε37-{2-(2-(2-(2-[2-(2-(4-(hexadecanoylamino)-4-carboxybutyryl-amino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-[desaminoHis7,Glu22,Arg26,Glu30,Arg34,Lys37]GLP-1-(7-37)amide, N-ε37-{2-(2-(2-(2-[2-(2-(4-(hexadecanoylamino)-4-carboxybutyryl-amino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-[desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37)amide, N-ε37-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(octadecanoyl-amino)ethoxy)ethoxy)acetate N-ε37-[4-(16-(1H-tetrazol-5-yl)hexadecanoylsulfamoyl)butyryl][desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37)amide, N-ε37-[2-(2-{2-[(S)-4-carboxy-4 GLP-1-(7-37), N-ε37-(2-{2-[2-((S)-4-carboxy-4-{(S)-4-carboxy-4-[(S)-4-carboxy-4-(19-carboxy-nonadecanoylamino)butyrylamino]butyrylamino}butyrylamino)ethoxy]ethoxy}acetate GLP-1-(7-37), N-ε37-{2-[2-(2-{(S)-4-[(S)-4-(12-{4-[16-(2-tert-butyl-2H-tetrazol-5-yl)-hexadecanoylsulfamoyl]butyrylamino}dodecanoylamino)-4-carboxybutyrylamino]-4-carboxybutyrylamino}ethoxy)ethoxy]acetyl}[desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1(7-37), N-ε37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl][Aib8,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37), N-α37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-heptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl][Aib8,Glu22,Arg26,Arg3 4,ε-Lys37]GLP-1-(7-37) peptide, N-ε37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxy-hexadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl][desaminoHis7,Glu22,Arg26,Arg34,Lys37]GLP-1-(7-37), N-ε36-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(15-carboxy-pentadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl][desaminoHis7, Glu22,Arg26,Glu30,Arg34,Lys36]GLP-1-(7-37)-Glu-Lys peptide, N-ε37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-({trans-4-[(19-carboxynonadecanoylamino)methyl]cyclohexanecarbonyl}amino)butyrylamino]ethoxy}ethoxy)acetylamino]ethoxy}ethoxy)acetyl GLP-1-(7-37), N-ε37-[2-(2-{2-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)-butyrylamino]-ethoxy}-ethoxy)-acetylamino]-ethoxy}-ethoxy)-acetyl]-[Aib8,Glu22,Arg26,Arg34,Aib35,Lys37]GLP-1-(7-37), N-ε37-[(S)-4-carboxy-4-(2-{2-[2-(2-{2-[2-(17-carboxyheptadecanoylamino)ethoxy]ethoxy}acetylamino)ethoxy]ethoxy}acetylamino)butyryl][Aib8,Glu22,Arg26,34,Lys37]GLP-1(7-37), N-ε37-[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetyl amino)ethoxy]ethoxy)acetyl] [ImPr7,Glu22,Arg26,34,Lys37],GLP-1-(7-37),N-ε26-{2-[2-(2-{2-[2-(2-{(S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butyrylamino}ethoxy)ethoxy]acetylamino}ethoxy)ethoxy]acetyl},N-ε37-{2-[2-(2-{2-[2-(2-{(S)-4-carboxy-4-[10-(4-carboxyphenoxy)decanoylamino]butyrylamino}ethoxy)ethoxy]acetyl} N-(2-carboxyethyl)-N-(15-carboxypentadecanoyl)amino]methyl}benzoyl[Arg34]GLP-1(7-37)-OH, N-ε26(17-carboxyheptadecanoyl)-[Aib8,Arg34]GLP-1-(7-37)-peptide, N-ε26-(19-carboxynonadecanoyl)-[Aib8,Arg34]GLP-1-(7-37), N-ε26-(4-{[N-(2-carboxyethyl)-N-(15-carboxypentadecanoyl)amino]methyl}benzoyl[Arg34]GLP-1(7-37)-OH, GLP-1-(7-37), N-ε26-[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Arg34]Arg34]GLP-1-(7-37), N-ε26-[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][3-(4-imidazolyl)propionyl 7,Arg34]GLP-1-(7-37), N-ε26-[2-(2-[2-(2-[2-(2-[ 4-(17-carboxyheptadecanoylamino)-(carboxymethyl-amino)acetylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37), N-ε26-[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-3(S)-sulfopropionylamino]ethoxy)ethoxy]acetoacetate, N-ε26-[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8,Arg34]GLP-1-(7-37), N-ε26-[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8,Arg34]GLP-1-(7-37), N-ε26-[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37)-amide, N-ε26-[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Arg34,Pro37]GLP-1-(7-37)amide, Aib8,Lys26(N-ε26-{2-(2-(2-[2-(2-(4 -(pentadecanoylamino)-4-carboxybutyrylamino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}),Arg34)GLP-1-(7-37)-OH, N-ε26-[2-(2-[2-(2-[2-(2-[4-{[N-(2-carboxyethyl)-N-(17-carboxyheptadecanoyl)amino]methyl}benzoyl)amino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Arg34]GLP-1(7-37), N-α7-formyl,N -ε26-[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoyl-amino)-4(S)-carboxy-butyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Arg34]GLP-1-(7-37), N-ε2626-[2-(2-[2-(2-[2-(2-[4-(17-carboxyheptadecanoyl-amino)-4(S)-carboxy-butyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Glu22,Arg34]GLP-1-(7-37), N-ε26{3-[2-(2-{2-[2-(2-{2-[2-(2-[4-(15-(N-((S)-1,3-dicarboxypropyl)carbamoyl)pentadecanoylamino)-(S)-4-carboxybutyrylamino]ethoxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy}ethoxy)ethoxy]propionyl}[Aib8,Arg34]GLP-1-(7-37), N-ε26-[2-(2-[2-(2-[2-(2-[4-{[N-(2-carboxyethyl) -N-(17-carboxy-heptadecanoyl)amino]methyl}benzoyl)amino](4(S)-carboxybutyryl-amino)ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Arg34]GLP-1(7-37), N-ε26-{(S)-4-carboxy-4-((S)-4-carboxy-4-((S)-4-carboxy-4-((S)-4-carboxy-4-(19-carboxy-nonadecanoylamino)butyrylamino)butyrylamino)butyrylamino)butyrylamino)butyrylamino)}[Aib8,Arg34]GLP-1-(7-37), N-ε26-4-(17-carboxyheptadecanoyl-amino)-4(S)-carboxybutyryl-[Aib8,Arg34]GLP-1-(7-37), N-ε26-{3-[2-(2-{2-[2-(2-{2-[2-(2-[4-(17-carboxyheptadecanoyl-amino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy}ethoxy)ethoxy]propionyl}[Aib8,Arg34]GLP- 1-(7-37), N-ε26-{2-(2-(2-(2-[2-(2-(4-(17-carboxyheptadecanoylamino)-4-carboxybutyrylamino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-[Aib8,22,27,30,35,Arg34,Pro37,Lys26]GLP-1(7-37)amide, N-ε26-[2-(2-[2-[4-(21-carboxyaneicosanoylamino)-4(S)-carboxybutyrylamino]ethoxy]ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37), and N-ε26-[2-(2-[2-(2-[2-(2-[4-(21-carboxyaneicosanoylamino)-4(S)-carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37).
[0107] The term solid dosage form refers to a tablet, a solid filled capsule, or a solution filled capsule.
[0108] As used herein, the terms "treat," "treating," "treatment," and the like refer to eliminating, reducing, or ameliorating a disease or condition and / or its associated symptoms. Although not excluded, it will be understood that treating a disease or condition does not require that the disease, condition, or its associated symptoms be completely eliminated.
[0109] As used herein, the term "therapeutically effective amount" refers to an amount of a therapeutic agent (e.g., semaglutide) sufficient to result in amelioration of one or more symptoms of a disorder or condition (e.g., type 2 diabetes), or to prevent the onset or progression of a disorder or condition, or to cause regression or cure of a disorder or condition.
[0110] The term "subject" (also referred to herein as "patient"), as used herein, refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment. EXAMPLES
[0111] Example 1. This example shows that the combination of semaglutide with SNAC and sodium caprate unexpectedly results in higher drug absorption and more effective glucose control than SNAC alone. The effective enhancement based on the plasma concentration of semaglutide is about 5-fold. Furthermore, the superior pharmacological effect of semaglutide based on the oral glucose tolerance test (oGTT) was also demonstrated with the combination of semaglutide with SNAC and sodium caprate.
[0112] Preparation of formulations Appropriate amounts of drug (e.g., sodium semaglutide) and excipients, such as SNAC or SNAC and sodium caprate ("C10"), and any other excipients, if present, were mixed in water to form a solution, which was then lyophilized to obtain the formulation.
[0113] A typical procedure for preparing a formulation containing semaglutide, SNAC and C10: Semaglutide sodium is weighed out and placed into a glass vial. Approximately 15 ml of water is added to dissolve each 65 mg of semaglutide sodium. SNAC is then weighed out and added to the above aqueous semaglutide solution. A stir bar is used for stirring. Sodium caprate (and other excipients, if required) is then added to the solution and the solution is stirred to dissolve all excipients. The solution is then lyophilized.
[0114] Formulation 1 prepared according to this procedure contains 10 mg semaglutide and 300 mg SNAC. Formulation 2 prepared according to this procedure contains 10 mg semaglutide, 300 mg SNAC and 150 mg sodium caprate.
[0115] The freeze-dried powder was then processed into tablets and used in the examples herein. Tablets were formed using a manual compressor, a 12 mm diameter circular tablet die, and an arc on the die surface.
[0116] Example 2A. Pharmacokinetic studies and oral glucose tolerance tests This example describes pharmacokinetic ("PK") studies of oral semaglutide formulations. For each PK study, an oGGT study is also performed on the first day of the study.
[0117] The dogs were kept in separate cages. Before the experiment, the dogs were fed twice a day, at around 3 pm and 7 am. The food was provided in a bowl with water. On the day before the experiment, the dogs were fed at 3 pm and then fasted overnight for approximately 18 hours. The dogs were allowed to drink water during the night, but the water was removed 1 hour before dosing. Before dosing, the dogs were placed in a sling, and then 0.8 ml of blood was taken from the leg vein of each dog using a sterile disposable syringe.
[0118] Oral administration of tablets: Open the cage and allow the dog to climb into the cage with its front legs. Grab the mouth and open it with your hand. While holding the dog's mouth open, the worker inserts the tablet into the dog's throat with his fingers. Then close the dog's mouth and keep it closed for about 10 seconds. The dog will swallow the tablet naturally without water.
[0119] After dosing, 0.8 ml blood samples were collected from the front leg vein of the dogs into EDTA anticoagulant tubes at the following time points: 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, and 168 h. After mixing by inversion several times, the blood samples were centrifuged at 3500 rpm for 10 min. The supernatant plasma samples were removed to wash the tubes and stored at -60°C in a freezer before measurement. After the 8-h sample was collected, the dogs were released and immediately given food and water.
[0120] An LC-MS method with MRM mode is used to measure the plasma concentration of semaglutide. 150 μl acetonitrile containing internal standard was added to 50 μl plasma to precipitate proteins. After vortexing for 30 seconds, the samples were sonicated for 2 minutes. The samples were centrifuged at 15400G for 10 minutes. The supernatant was then removed for analysis. Mass spectrum was AB (Triple Quad6400+), SHIMADZU. Sepax Bio-C18 (4.6*150mm, 5mm) was used. The parameters of LC-MS are summarized below: Mobile phase: A: HO (0.1% formic acid and 5 mM ammonium acetate; B: ACN (0.2% formic acid) Flow rate: 1ml / min Column temperature: 40℃ CAD(psi):12 Gas 1(psi):60 IS(V):5500 CUR(psi):40 Gas 2(psi):55 TEM(℃):600 Mode: ESI / + Semaglutide ion pair: 1029.2 m / z ~ 136.1 m / z, collision energy 100V.
[0121] As explained above, for each PK experiment, an oGTT experiment was also performed on the first day of the experiment. 3.5 hours after administration of semaglutide, sampling was started at -30 min for glucose level measurement. Blood samples at times t = -15 min and 0 min were collected for glucose measurement. After measuring background glucose levels, a disposable syringe without a needle was used to inject glucose solution (0.3 mg / ml) into the dog's mouth, based on a dose of 1.5 g glucose / kg. The dog's mouth was then closed to ensure that the dog swallowed the solution. This operation may need to be repeated 5-6 times, since only about 10 ml of solution can be administered to the dog at one time. After completion of glucose administration, glucose concentrations were measured from the blood samples using a glucometer at the following time points: t = 15 min, 30 min, 45 min, 1 h, 2 h, and 3 h.
[0122] The glucometer was purchased from Yuyue Medicals (https: / / www.yuwell.com / index_en.php / Group / read / id / 3). Systemic glucose was measured by drawing a blood sample of approximately 0.05 ml from a vein in the dog's front leg. A drop of blood was then pushed into the needle and allowed to remain at the tip of the needle for a few seconds. A glucose test strip previously inserted into the glucometer was used to draw the above drop of blood from the tip of the needle. The glucometer then automatically started measuring, and the result was obtained approximately 8 seconds later. The measured glucose level was immediately recorded and the test strip was removed.
[0123] Test Results: The pharmacokinetics of semaglutide and the corresponding pharmacodynamics from oGGT measurements are summarized in the results of experiments in beagle dogs.
[0124] The terminal half-life of semaglutide was determined based on the terminal log-linear phase. The area under concentration time (AUC) of semaglutide was calculated using the linear trapezoidal method. Inter-individual variability was assessed by the coefficient of variation (CV), calculated as the standard deviation divided by the mean.
[0125] Semaglutide + SNAC In this study, oral formulations containing 10 mg and 300 mg of semaglutide and SNAC, respectively, were administered to dogs as described above. The concentration-time profile of semaglutide is shown in Figures 1 and 2. The mean pharmacokinetic parameters (N = 6 dogs) are summarized in Table 1. The mean Tmax was approximately 1 hour, suggesting rapid absorption facilitated by SNAC as a carrier. The terminal half-life in dogs was approximately 43 hours. The mean C_max and AUC_infinity were approximately 16 nM and 647 h.nM, respectively. The corresponding interindividual variability (IIV) was measured by the coefficient of variation.
[0126] Semaglutide + SNAC + sodium caprate In this study, oral formulations containing 10 mg, 300 mg and 150 mg of semaglutide, SNAC and sodium caprate, respectively, were administered to dogs as described above. The concentration-time profiles of semaglutide are shown in Figures 1 and 2. The mean pharmacokinetic parameters are summarized in Table 1. The mean Tmax was approximately 1 hour, suggesting rapid absorption facilitated by SNAC and sodium caprate as carriers. The terminal half-life in dogs was approximately 43 hours. The mean C_max and AUC_infinity were approximately 90 nM and 3125 nM, respectively. TIFF2024541120000011.tif52165
[0127] Compared to the formulation containing SNAC alone, the formulation containing SNAC and sodium caprate showed substantial improvements in AUC and Cmax, which were approximately 4.8-fold and 5.9-fold higher, respectively. The CVs of Cmax and AUC were also significantly reduced, which is clinically important, because smaller inter-individual variability means that patient dosing is safer (fewer patients receive unnecessarily high exposures) and more effective (fewer patients receive sub-therapeutic exposures).
[0128] Oral glucose tolerance test (oGTT): The oral dose of glucose used in this experimental study is 1.5 g glucose / kg. The concentration-time profiles of glucose from formulations containing only semaglutide 10 mg and SNAC 300 mg, and formulations containing semaglutide 10 mg, SNAC 300 mg and sodium caprate 150 mg are shown in Figure 3. The oGTT reflects the pharmacodynamic modulation of glucose absorption and disposal by GLP-1 receptor agonists (Courtney Moore, et al., Am J Physiol Endocrinol Metab. 2013Dec15;305(12):E1473-E1482). Semaglutide 10 mg and SNAC alone slightly improved glucose control compared to the control group (without semaglutide), especially the early improvement at 0.25 hours. In contrast, the combination of semaglutide 10 mg with SNAC and sodium caprate demonstrated greater glucose control than semaglutide 10 mg with SNAC alone, indicating that the measured semaglutide concentrations were pharmacodynamically effective, consistent with improved plasma pharmacokinetics with the combination of SNAC and sodium caprate.
[0129] Example 3. This example examines (1) the effect of using SNAC alone, C10 alone, or a combination of SNAC and C10 on the bioavailability of semaglutide, (2) the effect of using lyophilization versus simple mixing on the bioavailability of semaglutide, and (3) a comparison of a representative formulation of the present application using a commercially available tablet (Rebelsus 7 mg).
[0130] Preparation of formulations For samples using lyophilization as the blending process, the preparation process is as follows: Appropriate amounts of drug (e.g., semaglutide sodium) and excipients, e.g., SNAC alone, or sodium caprate ("C10") alone, or SNAC and C10 together, and any other excipients, if present, were mixed in water to form a solution. The solution was then lyophilized to obtain the formulation.
[0131] A typical procedure for preparing a formulation containing semaglutide, SNAC and C10: Semaglutide sodium is weighed out and placed into a glass vial. Approximately 15 ml of water is added to dissolve each 65 mg of semaglutide sodium. C10 is then weighed out and added to the above aqueous semaglutide solution. A stir bar is used for stirring. SNAC (and other excipients, if required) is then added to the solution and the solution is stirred to dissolve all the excipients. The solution is then lyophilized to obtain a dry mixture.
[0132] For samples using simple blending as the blending process, the preparation process is as follows: appropriate amounts of drug (e.g., semaglutide sodium) and excipients (e.g., SNAC and sodium caprate ("C10")), and any other excipients, if any, were mixed in a mortar or shaken up and down in a plastic bag for at least 10 minutes. Then, a mixture by simple blending was obtained.
[0133] Powders produced by freeze drying or simple blending were then processed into tablets and used in the examples herein. Tablets were formed using a 10 mm diameter circular tablet mold and a manual compressor with a circular mold surface.
[0134] Pharmacokinetic experiments and LC / MS assays This example describes pharmacokinetic ("PK") studies of oral semaglutide formulations.
[0135] The dogs were kept in separate cages. Before the experiment, the dogs were fed twice a day, at around 3 pm and 7 am. The food was provided in a bowl with water. On the day before the experiment, the dogs were fed at 3 pm and then fasted overnight for approximately 18 hours. The dogs were allowed to drink water during the night, but the water was removed 1 hour before dosing. Before dosing, the dogs were placed in a sling, and then 0.8 ml of blood was taken from the leg vein of each dog using a sterile disposable syringe.
[0136] Oral administration of tablets: Open the cage and allow the dog to climb into the cage with its front legs. Grab the mouth and open it with your hand. While holding the dog's mouth open, the worker inserts the tablet into the dog's throat with his fingers. Then close the dog's mouth and keep it closed for about 10 seconds. The dog will swallow the tablet naturally without water.
[0137] After dosing, 0.6 ml blood samples were collected from the front leg vein of the dogs into EDTA anticoagulant tubes at the following time points: pre-dose, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 24 h, and 48 h. After mixing by inversion several times, the blood samples were centrifuged at 3500 rpm for 10 min. The supernatant plasma samples were removed to wash the tubes and stored at -60°C in a freezer before measurement. After collection of the 6-h sample, the dogs were released and immediately provided with food and water.
[0138] An LC-MS method with MRM mode is used to measure the plasma concentration of semaglutide. 150 μl acetonitrile containing internal standard was added to 50 μl plasma to precipitate proteins. After vortexing for 30 seconds, the samples were sonicated for 2 minutes. The samples were centrifuged at 15400G for 10 minutes. The supernatant was then removed for analysis. Mass spectrum was AB (Triple Quad6400+), SHIMADZU. Sepax Bio-C18 (4.6*150mm, 5mm) was used. The parameters of LC-MS are summarized below: Mobile phase: A: HO (0.1% formic acid and 5 mM ammonium acetate; B: ACN (0.2% formic acid) Flow rate: 1ml / min Column temperature: 40℃ Mode: ESI / + Semaglutide ion pair: 1029.2 m / z ~ 136.1 m / z.
[0139] result: As shown in Figure 4, the use of the SNAC (300 mg) / C10 (150 mg) combination significantly increased the bioavailability of semaglutide and improved the PK profile compared to the marketed tablet Ryvelsus. The details of the PK parameters are also shown in Table 2 below, with an improvement of approximately 10-fold in AUC and nearly 14-fold in Cmax. TIFF2024541120000012.tif49165
[0140] As shown in Figure 5, preparing the formulation using lyophilization is beneficial for enhancing the bioavailability of semaglutide, resulting in a much better PK profile compared to the formulation prepared by simple blending. The detailed PK parameters are also shown in Table 3 below, with an approximately 4-fold improvement in AUC and approximately 4-fold improvement in Cmax. TIFF2024541120000013.tif50165
[0141] As shown in Figure 6, the use of SNAC in combination with C10 achieved synergistic effects and a much better PK profile compared to the use of SNAC or C10 alone. Details of the PK parameters are also shown below in Table 4. As shown in Table 4, the additive effect of 300 mg SNAC and 300 mg C10 is less than that observed with the SNAC / C10 combination (even at the lower dose of C10) in both AUC and Cmax. TIFF2024541120000014.tif66165
[0142] It should be appreciated that it is intended that the Detailed Description section, rather than the Summary and Abstract sections, be used to interpret the claims. The Summary and Abstract sections may set forth one or more, but not all, exemplary embodiments of the invention as contemplated by the inventor(s) and are not intended to limit the scope of the invention and the appended claims in any manner.
[0143] The present invention has been described above using functional components that indicate the implementation of specific functions and their relationships. The boundaries of these functional components have been arbitrarily defined herein for the convenience of description. Alternative boundaries may be defined as long as the specific functions and their relationships are appropriately implemented.
[0144] For aspects of the invention described as genus, all individual species are separate aspects of the invention considered individually. When aspects of the invention are described as "comprising" an element, embodiments "consisting of" or "consisting essentially of" that element are also contemplated.
[0145] The above specific description of specific embodiments fully illustrates the general nature of the present invention, so that others can easily modify and / or adapt such specific embodiments to various applications by applying knowledge within the skill of the art without undue experimentation and without departing from the general concept of the present invention. Therefore, such adaptations and modifications are intended to be within the meaning and range of equivalents of the disclosed embodiments based on the teachings and advice presented herein. The words or terms used herein are for the purpose of description and not for the purpose of limitation, and the words or terms used herein should be understood by those skilled in the art in light of the teachings and advice presented herein.
[0146] The breadth and scope of the present invention should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents.
[0147] Any of the various aspects, embodiments, and options described herein can be combined in any and all variations.
[0148] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, and patent application was specifically and individually indicated to be incorporated by reference. If any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition of the term in this document shall control.
Claims
1. (a) a polypeptide; (b) a fatty acid of formula I: RCOOH, where R represents an aliphatic group, or a pharma- ceutically acceptable salt thereof; and (c) A compound of formula II: 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof, wherein n is an integer selected from 0, 1, 2, 3, or 4; 1 are independently OH, NH 2 , NH(C 1~4 Alkyl), N(C 1~4 Alkyl) (C 1~4 alkyl), halogen (e.g., Cl), C 1 ~ 4 Alkyl, or C 1 ~ 4 Alkoxy (e.g., OCH 3 ) and L 1 is a substituted or unsubstituted C 2 ~C 16 Alkylene, or substituted or unsubstituted C 2 ~C 16 alkenylene). Pharmaceutical compositions.
2. 10. The pharmaceutical composition of claim 1, formulated for oral administration.
3. 3. The pharmaceutical composition of claim 1 or 2, which, when orally administered to a human subject in need thereof, delivers a therapeutically effective amount of the polypeptide to the human subject.
4. In formula I, R represents an alkyl group having 1 to 30 carbon atoms, for example, R is -(CH 2 ) 1~18 CH 3 The pharmaceutical composition according to any one of claims 1 to 3,
5. The pharmaceutical composition according to any one of claims 1 to 3, wherein in formula I, R represents an alkyl group having from 3 to 20 carbon atoms.
6. The pharmaceutical composition according to any one of claims 1 to 3, wherein in formula I, R represents an alkyl group having from 5 to 16 carbon atoms.
7. The fatty acids of formula I are straight chain fatty acids having from 2 to 20 carbon atoms, such as caprylic acid, capric acid, or lauric acid. The pharmaceutical composition according to any one of claims 1 to 3.
8. The pharmaceutical composition according to any one of claims 1 to 7, wherein in formula II, n is 0.
9. In Formula II, n is 1 and G 1 is halogen, C 1 ~ 4 Alkyl, or C 1 ~ 4 The pharmaceutical composition according to any one of claims 1 to 7, wherein the compound is alkoxy.
10. In Formula II, n is 1 and G 1 is Cl, or OCH 3 The pharmaceutical composition according to any one of claims 1 to 7,
11. In formula II, L 1 is a substituted or unsubstituted C 2 ~C 16 The pharmaceutical composition according to any one of claims 1 to 10, wherein the alkylene is alkylene.
12. In formula II, L 1 is unsubstituted C 3 ~C 15 The pharmaceutical composition according to any one of claims 1 to 10, wherein the alkylene is alkylene.
13. In formula II, L 1 is unsubstituted C 5 ~C 13 The pharmaceutical composition according to any one of claims 1 to 10, wherein the alkylene is alkylene.
14. In formula II, L 1 is an unsubstituted linear C 5 ~C 9 The pharmaceutical composition according to any one of claims 1 to 10, wherein the alkylene is alkylene.
15. 15. The compound of formula II 【Chemistry 2】 The pharmaceutical composition according to any one of claims 1 to 7,
16. The compound of formula II is 【Chemistry 3】 The pharmaceutical composition according to any one of claims 1 to 7,
17. A pharmaceutical composition according to any one of claims 1 to 16, comprising the sodium salt of the compound of formula II.
18. 【Chemical 4】 The pharmaceutical composition according to any one of claims 1 to 3, comprising a sodium salt of
19. 20. The pharmaceutical composition of claim 18, wherein the fatty acid of formula I is capric acid.
20. 20. The pharmaceutical composition according to any of claims 1 to 19, wherein the weight ratio of (b) the fatty acid of formula I or a pharma- ceutically acceptable salt thereof to (c) the compound of formula II or a pharma- ceutically acceptable salt thereof, (b) / (c), is in the range of about 20:1 to about 1:20, such as 5:1 to 1:5, such as about 3:1, about 2:1, about 1:1, about 1:1.5, about 1:2, about 1:2.5 or about 1:3, or any range between the recited values, such as about 1:
2.
21. The pharmaceutical composition of any of claims 1 to 20, wherein the fatty acid of formula I or a pharma- ceutically acceptable salt thereof is in an amount of about 50 mg to about 300 mg per unit dose.
22. The pharmaceutical composition of any of claims 1 to 21, wherein the compound of formula II or a pharma- ceutically acceptable salt thereof is in an amount of about 200 mg to about 400 mg per unit dose.
23. 23. The pharmaceutical composition of any of claims 1 to 22, comprising a synergistic combination of (b) a fatty acid of formula I, or a pharma- ceutically acceptable salt thereof, and (c) a compound of formula II, or a pharma- ceutically acceptable salt thereof, for enhancing oral delivery of the polypeptide.
24. The pharmaceutical composition according to any one of claims 1 to 23, wherein the polypeptide is a glucagon-like peptide-1 (GLP-1) receptor agonist (see, for example, US Pat. No. 1,096,052).
25. The pharmaceutical composition of any one of claims 1 to 22, wherein the polypeptide is semaglutide, liraglutide, dulaglutide, lixisenatide, or exenatide.
26. The pharmaceutical composition of any one of claims 1 to 25, further comprising an SGLT-2 inhibitor such as empagliflozin, canagliflozin, dapagliflozin, or ertugliflozin.
27. 27. The pharmaceutical composition of any one of claims 1 to 26, further comprising a DPP-4 inhibitor, such as sitagliptin, vildagliptin, saxagliptin, linagliptin, or alogliptin.
28. The pharmaceutical composition according to any one of claims 1 to 27, further comprising insulin.
29. The pharmaceutical composition of any of claims 1 to 28, further comprising a lubricant, a binder, a filler, and / or a chelating agent (e.g., ethylenediaminetetraacetate (EDTA)).
30. 30. The pharmaceutical composition of any of claims 1 to 29, which is in a solid oral dosage form, such as a capsule or tablet.
31. 31. A method of treating a disease or disorder, such as type 2 diabetes or obesity, in a subject in need thereof, comprising orally administering a pharmaceutical composition according to any one of claims 1 to 30, thereby delivering a therapeutically effective amount of the polypeptide to the subject.
32. 31. A method of preparing a pharmaceutical composition according to any of claims 1 to 30, comprising: (a) mixing a polypeptide with a compound of formula II, or a pharma- ceutically acceptable salt thereof, and a fatty acid of formula I, or a pharma- ceutically acceptable salt thereof; (b) lyophilizing the mixture formed in (a) to form a lyophilized mixture; and, optionally, (c) mixing the lyophilized mixture with a pharma- ceutically acceptable excipient.
33. 1. A method for preparing a composition comprising a polypeptide, the method comprising: (a) coupling a polypeptide to a compound of formula II: 【Chemistry 5】 or a pharma- ceutically acceptable salt thereof, wherein n is an integer selected from 0, 1, 2, 3, or 4; 1 are independently OH, NH 2 , NH(C 1~4 Alkyl), N(C 1~4 Alkyl) (C 1~4 alkyl), halogen (e.g., Cl), C 1~4 Alkyl, or C 1~4 Alkoxy (e.g., OCH 3 ) and L 1 is a substituted or unsubstituted C 2 ~C 16 Alkylene, or substituted or unsubstituted C 2 ~C 16 alkenylene; and (b) freeze-drying the mixture formed in (a).
34. 34. The method of claim 33, wherein the combining in (a) comprises combining the polypeptide with a sodium salt of the compound of formula II.
35. The mixing in (a) comprises mixing the polypeptide 【Chemistry 6】 35. The method of claim 33 or 34, comprising mixing with the sodium salt of
36. The method of any one of claims 33 to 35, wherein the polypeptide is semaglutide, liraglutide, dulaglutide, lixisenatide, or exenatide.
37. 37. The method of any one of claims 33 to 36, wherein the mixing in (a) further comprises mixing the polypeptide, a compound of formula II or a pharma- ceutically acceptable salt thereof, and a fatty acid of formula I: RCOOH, where R represents an aliphatic group, or a pharma- ceutically acceptable salt thereof.
38. The method of claim 37, wherein the fatty acid of formula I is a straight chain fatty acid having from 2 to 20 carbon atoms, such as caprylic acid, capric acid or lauric acid.
39. 39. The method of any of claims 37-38, wherein the weight ratio of (i) the fatty acid of formula I or a pharma- ceutically acceptable salt thereof to (ii) the compound of formula II or a pharma- ceutically acceptable salt thereof, (i) / (ii), is in the range of about 20:1 to about 1:20, such as 5:1 to 1:5, such as about 3:1, about 2:1, about 1:1, about 1:1.5, about 1:2, about 1:2.5 or about 1:3, or any range between the recited values, such as about 1:
2.
40. 40. The method of any of claims 37-39, wherein the fatty acid of formula I or a pharma- ceutically acceptable salt thereof is in an amount of about 50 mg to about 300 mg.
41. The method of any of claims 33-40, wherein the compound of formula II or a pharma- ceutically acceptable salt thereof is in an amount of about 200 mg to about 400 mg.
42. A composition prepared by the method of any one of claims 33 to 41.
43. 43. A method of preparing a pharmaceutical composition comprising mixing a compound of claim 42 with a pharma- ceutically acceptable excipient.
